TRENDING

Tirupati SVU Alumnus in the Club of Global, Nobel Scientists

December 19, 2020
Trending News
Prof P. Hemachandra Reddy, Ph.D, an alumnus of  Sri Venkateswara Univerity, Tirupati, Andhra Pradesh, and now a scientist at the Texas Tech University Health Sciences Center (TTUHSC), has been elected a Fellow of the American Association for the Advancement of Science (AAAS).
This is a rare honor bestowed upon AAAS members by their peers and based upon the nominee’s scientifically or socially distinguished efforts to advance science or its applications.
Prof  Hemachandra Reddy has researched healthy aging, dementia, and other neurodegenerative diseases for over 20 years.
Prof Hemachandra Reddy who hails from the tiny village of Mllamgunta near Tirupati is a product of Sri Venkateswara University, Tirupati, Andhra Pradesh.
He did his M.Sc from the Department of Physical Anthropology and Pre-historic Archaeology (PAPA) with a specialization in cytogenetics. This is unbelievable that a student from SVU scaled that height in the field of medical genetics with special reference to the process of aging and its consequences.
Mallamkunta village (Pic credits: Aluri Raghava Sarma, Tirupati
painfully, the Department of Physical Anthropology and Pre-historic Archaeology (PAPA) is no longer exists now at it was merged with the department of sociology, an indication of Indian Universities’ malignant indifference towards a branch of Human socio-biology.
Though the branch has been contributing immensely to the understanding of human communities and biology, as an academic faculty, the department of Physical Anthropology is on the verge of extinction in India. Thanks to UPSC, Antrhrogpoly is flourishing outside universities and is the most sought after subject for the aspirants of Civil Services.
Considered one of the brilliant students of the small and most neglected department of SVU, Hemachandra gifted with a  smile that never disappears on his face and an immense flair for the research behind it.
The foundation for the future scientist of an extraordinary caliber was laid on the day when he, along with his classmates, fought for the introduction of trending specializations such as Cytogenetics, Human Population genetics, and Forensic Anthropology. Hem opted for Cytogenetics. Four years later, after passing out from the university, Hem secured the prestigious commonwealth fellowship to do his Ph.D. in UK.
The breakthrough in his research career came when he could not secure a job in India, with a doctorate from a prestigious UK university even after attending a dozen interviews.
This led him to the other side of the Atlantic, the US, for post-doctoral which eventually landed him in the Genome project, launched by none other than James Watson of DNA fame.
pic source: SVU website
Had he been selected for the Indian university job, Prof Hemachandra Reddy would certainly have stuck deep in petty politics and become at best Vice-Chancellor of a university.
The AAAS elected 489 of its members as Fellows in 2020. Reddy was elected in the Biological Sciences category for his pioneering contributions to the fields of Alzheimer’s disease and mitochondrial neurobiology, particularly in discovering the key role of mitochondria in neurodegenerative diseases and their treatment. Mitochondria, considered the power generators of cells, take in and breakdown nutrients to create high-energy molecules for the cell.
AAAS says Reddy’s experience and contributions benefit several TTUHSC schools and departments. He is a professor in the Department of Internal Medicine at the TTUHSC School of Medicine, one of the university’s largest research divisions that encompasses nationally and internationally recognized and research grant-funded faculty studying additional fields, including tropical medicine/infectious disease, hematology/oncology, nephrology and cardiopulmonary disease.
He also serves as a professor in the Department of Pharmacology and Neuroscience at the School of Medicine, the Department of Public Health at the TTUHSC Graduate School of Biomedical Sciences and the Department of Speech, Language and Hearing Sciences in the TTUHSC School of Health Professions. He became a member of AAAS about five years ago and said becoming an AAAS Fellow is an honor both professionally and personally.
“The election of Fellows is purely based on pioneering contributions to science over a lifetime, so it is a great honor to be recognized as a Fellow of AAAS,” Reddy said.
Reddy’s lab has published more than 180 peer-reviewed articles related to Alzheimer’s disease and mitochondria research. According to the Google Scholar website, his articles have been cited 16,579 times with an H-Index of 66 and an i10-Index of 128. The h-index is used to measure a researcher’s scientific productivity and the impact of their research upon science. The i10 index is the number of publications a researcher has produced that have received at least 10 citations.
In addition, the Reddy lab is actively investigating chronic conditions such as diabetes, obesity, cardiovascular disease, kidney disease, stroke, vascular dementia and other factors that are associated with dementia.
Reddy also was elected a Fellow of the American Neurological Association in 2014. Though the accolades and recognition are nice, Reddy believes groups like the ANA and AAAS are valuable because of the relationships and opportunities that come from meeting and learning from other scientists.
“I have come to know a large number of fellow researchers and scientists in almost all scientific communities,” Reddy said. “It opens my eyes; how biological and human science is moving forward. I sincerely thank all my current and former lab members for their sincere efforts and my collaborators and peers who supported me all through my research career. Last, but not least, I thank my parents and family members for their support and for understanding my passion for Alzheimer’s Science.”

(with inputs from a press release from American Association for the Advancement of  Science, AAAS)

Mind-boggling CV of Prof Hemachandra Reddy

  1. HEMACHANDRA REDDY, Ph.D.

Curriculum Vitae

__________________________________________________________________________________

 

Mailing Address                    Texas Tech University Health Sciences Center

3601 4th Street / Stop:  9410 / 4B 207

Lubbock, Texas 79430

 

Residential Address             4910 19th Street, Lubbock, TX 79407

 

Date of Birth                          February 15, 1961

 

 

Present Position:   Tenured Professor of Internal Medicine, Neurology and Neuroscience/Pharmacology Departments, djunct Professor of Speech, Language and Hearing Sciences Department, Professor of Public Health Department, GSBS, Texas Tech University Health Sciences Center (TTUHSC),3601 4th Street / 4B 207, Lubbock, Texas 79430

 

Fellow of the American Association for the Advancement of Science 2020

Fellow of American Neurological Association since 2014

Member of Post Tenure Committee, TTUHSC, 2018-2020

Member of Tenure and Promotions Committee, GSBS, TTUHSC, 2019-2022

 

Previous Positions:    Regular Member of Neuronal Oxidative Metabolism and Death (NOMD)

NIH Study Section – 2013-2019

Chair (2017-2018) and member of School of Medicine (SOM) Research Executive Committee, TTUHSC 2016-2019

Member of Faculty Development Leave Committee, TTUHSC 2015-2018, Chair (2018)

Member of Medical Students Promotion Committee, TTUHSC 2016-2018

Member of University Research Council, TTUHSC 2017-2018

Executive Director, Garrison Institute on Aging (Oct 2014-Feb 2019)

Texas Tech University Health Sciences Center,3601 4th Street / 4A 124A, Lubbock, Texas 79430

Associate Scientist or Associate Professor (October 2009-September 2014), Oregon National Primate Research Center, West Campus, OHSU

Assistant Scientist or Assistant Professor (July 2008-September 2009) Oregon National Primate Research Center, West Campus, OHSU, Assistant Scientist or Assistant Professor (2000 July – June 2008) Neurological Sciences Institute, West Campus, OHSU

 

IACUC member, West Campus, OHSU 2006-2012

Chemical use sub-committee member, OHSU 2009-2012

Regular member, VA Merit Review NeuroD Committee, 2007-2011.

Research Interests

Molecular and Cell Biology, Gene Expression Analysis, MicroRNA Studies,

Transgenic Mouse Models, Aging, Neurodegenerative Diseases, Mitochondrial Biology, Mitochondrial Function/Dysfunction and Mitochondrial Therapeutics

Education

1995-2000:   Postdoctoral Training, National Human Genome Research Institute, NIH

1994-1995:  Postdoctoral Training, University College, London University, London

1990-1994: Ph.D. in Human Genetics from University College, London

1985-1987:  M. Phil in Human Cytogenetics from Delhi University

1982-1984:                             M.Sc. in Human Biology from Sri Venkateswara University, Tirupati, India, Obtained third position

1978-1981: B.Sc. in Biology with majors Botany, Zoology and Chemistry in  from Sri Venkateswara University, Tirupati, India

 

Honors and Awards

2014: Elected Fellow of American Neurological Association (FANA)

2016: Received Bharat Gaurav Award from Govt and Friendship Society of India

2020: Elected  Fellow of American Association for the Advancement of Science (FAAAS)

2021/2022: Being nominated for National Academy of Sciences, USA

2014: Guest Editor for a Special Issue – Misfolded Proteins, Mitochondrial Dysfunction and Neurodegenerative Disease in BBA Molecular Basis of Disease

2012: Opponent (external examiner) for a doctoral thesis from Karolinska Institute, Stockholm, Sweden.

2011: Academic Editor for PLOS ONE

2011: Forum/Guest Editor for a Special Issue – Aging and Mitochondria in Alzheimer’s Disease (for Antioxidants & Redox Signaling).

2009: Guest Editor of a Special Issue – Synaptic Damage in Aging and Neurodegenerative Diseases (for Frontiers in Aging Neuroscience)

2009: Guest Editor of Special Issues – Mitochondrial Drugs for Neurodegenerative Disease and Genes, Mechanisms and Drugs for Asthma (Pharmaceuticals – Molecular Diversity Preservation International (MDPI)

2009-present: Associate Editor, Frontiers in Aging Neuroscience

2007-Technology Transfer Innovations Award from Oregon Health and Science University

2006- Alzheimer Award for an outstanding paper “Differential loss of synaptic proteins in Alzheimer’s       disease: Implications for synaptic dysfunction” published in Journal of Alzheimer’s disease 7, 103-117

2003- Mentor Appreciation Award from Oregon Health and Science University

1999- Won a travel fellowship from Huntington’s Disease Society of America (HDSA) & presented a paper at 18th International Meeting of the World Federation of Neurology Research Group on Huntington’s Disease held in Hague, Netherlands, August 28-31, 1999

1999 – Fellows Award for Research Excellence (FARE Award) 1999 in Biomedical Research from National Institutes of Health, Bethesda, Maryland, USA

1999- 2000 Huntington Disease Society of America fellow

1995-1999: Visiting Fellowship from Fogarty International at National Institutes of Health (NIH), USA.

1994-1995; University College London post-doctoral Fellowship

1993-1994 Sir Halley Stewart Trust grant for laboratory expenses

1990-1994 Stopes Research Fund from Galton Institute, London, for field and laboratory expenses.

1990-1993 Commonwealth Scholarship from Great Britain, London

1985-1987 Junior Research Fellowship from Department of Science and Technology, Delhi

Membership/Fellowship of Scientific Bodies

Fellow of American Neurological Association

New York Academy of Sciences

American Public Health Association

American Federation Medical Research

Society for Neuroscience

Indian Society of Human Genetics

Galton Institute, London

Alzheimer’s Research Forum

Editorial Duties

2003-present: Ad Hoc Reviewer of Journal of Neurochemistry

2003-present: Ad Hoc Reviewer of Biotechniques

2003-present: Ad Hoc Reviewer of Briefings of Functional Genomics and Proteomics

2003-present: Ad Hoc Reviewer of Trends in Genetics

2004-present: Ad Hoc Reviewer of Journal of Neuroscience Methods

2004-present: Ad Hoc Reviewer of Journal of Neuroscience

2005-present: Ad Hoc Reviewer of Journal of Alzheimer’s Disease

2005-present: Ad Hoc Reviewer of Mitochondrion

2005-present: Ad Hoc Reviewer of Developmental Brain Research

2005-present: Ad Hoc Reviewer of Brain Research

2005-present: ad Hoc Reviewer of Brain Research Reviews

2005-present: Ad Hoc Reviewer of Neurobiology of Aging

2006-present: Ad Hoc Reviewer of Neuroscience

2007-present: Ad Hoc Reviewer of Rejuvenation Research

2007-present: Ad hoc Reviewer of Antioxidants and Redox Signaling

2007-present: Ad Hoc Reviewer of Trends in Molecular Medicine

2007-present: Ad Hoc Reviewer of Annals of Neurology

2007-present: Ad Hoc Reviewer of Journal of Neurology

2007-present: Ad Hoc Reviewer of Experimental Neurology

2007-present: Ad Hoc Reviewer of Antioxidants & Redox Signaling

2008-present: Ad Hoc Reviewer of Trends in Pharmacological Sciences

2008-present: Ad Hoc Reviewer of Open Longevity Science

2008-present: Ad Hoc Reviewer of Nature Medicine

2009-present: Ad Hoc Reviewer of PLoS ONE

2009-present: Ad Hoc Reviewer of Human Molecular Genetics

2009-present: Ad Hoc Reviewer of World Journal of Gastrointestinal Pharmacology and Therapeutics

2010-present: Ad Hoc Reviewer of Neurobiology of Disease

2010-present: Ad Hoc Reviewer of Metabolic Brain Disease

2010-present: Ad Hoc Reviewer of Frontiers in Neuropharmacology

2010-present: Ad Hoc Reviewer of Mini-Reviews in Medicinal Chemistry

2010-present: Ad Hoc Reviewer of Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry

2010-present: Ad Hoc Reviewer of Current Alzheimer Research

2011-present: Ad Hoc Reviewer of The Journal of Pharmacognosy

2011-present: Ad Hoc Reviewer of Journal of Gerontology: Biological Sciences

2011-present: Ad-Hoc Reviewer of Clinical Practice

2011-present: Ad Hoc Reviewer of World Journal of Methodology

 Editorial Board

2011-present: Associate Editor of Journal of Alzheimer’s Disease

2009-present: Associate Editor of Frontiers in Aging Neuroscience

2009-Present: Associate Editor of Frontiers Cell and Developmental Biology
2009-Present: Associate Editor of Frontiers in Chemistry

2009-Present: Associate Editor of Frontiers in Molecular Biosciences

2010-present: Associate Editor of Journal of Gerontology: Biological Sciences

2011-2014: One of the Editors-in-Chief of Clinical Practice

2011-present: Section Editor BBA-Molecular Basis of Disease

2011-present: Academic Editor of PLoS ONE

2012-present: Handling Editor of Journal of Alzheimer’s Disease and Parkinsonism

2014-present: Handling Editor of Journal of Neuroinfectious Diseases

2009-Present: Review Editor of Frontiers in Neuroscience

2009-Present: Review Editor of Frontiers in Pharmacology

2009-Present: Review Editor of Frontiers in Neurology

2009-Present: Review Editor of Frontiers in Psychiatry

2018-present: Handling Editor of Scientific Reports

 Editor

  1. Molecular Biology of Aging Book with Elsevier and Academic Press, Published March 1, 2017.

 

  1. Interphase Between Aging and Neurodegenerative Diseases, Published in January 2020 – With Frontiers in Aging Neuroscience – eBook.

 

Guest Editor

Guest Editor for 2 special issues in Pharmaceuticals (2010) –

  1. Mitochondrial Drugs for Neurodegenerative Disease and

2). Genes, Mechanisms and Drugs for Asthma in journal, Pharmaceuticals (2012) – Molecular Diversity Preservation International (MDPI)

 

  1. Guest Editor for a special issue (2012) ‘Current Status of Therapeutics and Preventive Measures for Patients with Thalassaemia and Sickle Cell Disease’ for Cardiovascular & Hematological Agents in Medicinal Chemistry

 

  1. Guest Editor for a special issue (2012) ‘Aging and Mitochondria in Alzheimer’s Disease in Antioxidants & Redox Signaling.

 

  1. Guest Editor for a special issue (2010) ‘Synaptic Damage in Aging and Neurodegenerative Diseases’ in Frontiers in Aging Neuroscience

 

  1. Guest Editor for a special issue (Aug 2014) ‘Misfolded Proteins, Mitochondrial Dysfunction and Neurodegenerative Disease’ in BBA Molecular Basis of Disease
  2. Guest Editor for a special issue (May 2017) ‘Oxidative Stress and Mitochondrial Quality in Diabetes/Obesity and Critical Illness Spectrum of Diseases’ in BBA Molecular Basis of Disease

 

  1. Guest Editor for a special issue (April 2017) ‘Neurotransmitters and Alzheimer’s Disease’ in Journal of Alzheimer’s Disease

 

  1. Guest Editor for a special issue (Dec 2019) ‘Healthy Aging and Dementia Research Symposium’ in Journal of Alzheimer’s Disease.

 

  1. Guest Editor for a special issue 2020 (April) ‘Stem Cells and Their Utility to Human Diseases’ in BBA Molecular Basis of Disease

 

  1. Guest Editor for a special issue 2019-2020 ‘Mitochondrial Dynamics – Fission and Fusion’ in Cells MDPI.

 

  1. Guest Editor for a special issue (2020) ‘Interphase Between Aging and Neurodegenerative Diseases’

in Frontiers in Aging Neuroscience.

 

  1. Guest editor for a special issue 2020 ‘Non-coding MicroRNAs and Neurodegenerative Diseases’ in Cells MDPI.

 

  1. Guest Editor for a special topic (2020-2021) ‘Mitochondrial dysfunction, the link between aging and Alzheimer’s disease’ in Frontiers in Aging Neuroscience.

 

Editorial Board

2008-present: Open Longevity Science Journal

2009-present: Frontiers in Aging Neuroscience
2009-present World Journal of Gastrointestinal Pharmacology and Therapeutics

2009-present: Cardiovascular & Hematological Agents in Medicinal Chemistry

2009-present: Pharmaceuticals

2010-present: Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry

2010-present Frontiers in Neuropharmacology

2010-present: BBA Molecular Basis of Disease

2010-present: Metabolic Brain Disease

2010-present: Mini-Reviews in Medicinal Chemistry

2010-present: Current Alzheimer Research

2011-present: Journal of Alzheimer Disease

2011-present: PLOS ONE

2011-present: The Journal of Pharmacognosy

2011-present: World Journal of Methodology

2011-present: World Journal of Translational Medicine

2011-present: Journal of Physiology and Pharmacology Advances

2012-present: Antioxidants (MDPI)

2012-present: Journal of Alzheimer’s Disease and Parkinsonism

2014-present: Journal of Neuroinfectious Disease

2012-present: Journal of Gerontology Biological Sciences

 Grant Reviewing Duties

2002-present: Reviewer of American Federation for Aging Research

2003-Ad Hoc Reviewer of USA Civilian Research and Development Foundation

2003-present: Reviewer of Alzheimer’s Association (National)

2005-present: Medical Research Council, London

2005-2009: Reviewer of NIH study section (CDIN)

2007 (June meeting): Ad-Hoc Reviewer of NIH study section (CND)

2007 (November 13, meeting) Reviewer of Special Emphasis Panel, NIH study section (ZMH1-ERB C2)

2008 Reviewer of Special Emphasis Panel, MDCN-D02 (October 15, 2008)

2009-present: Ad-Hoc Reviewer of Medical Research Council, London

2009 (April 20-21) Special Emphasis Panel Reviewer of study section, MDCN3

2009-Ad Hoc Reviewer of Special Emphasis Panel BDCN-T (ARRA grants)

2009-Ad Hoc Reviewer of Special Emphasis Panel MDCN-A (ARRA grants)

2009-Ad Hoc Reviewer of Special Emphasis Panel MDCN-G-02 – Neuroprotection (October 26, 2009)

2010-Ad Hoc Reviewer of Special Emphasis Panel, Member Conflict-BDCN-Y-02-M (February 25).

2010-Ad Hoc Reviewer of Special Emphasis Panel MDCN-P-03 – (April 20, 2010)

2010-Ad Hoc Reviewer Member Conflict: Molecular and Cellular Neuroscience, MDCN-A (July 15) M

2010-Ad Hoc member of NOMD study section October 4-5.

2010-Ad Hoc Reviewer of Neurodegeneration Special Emphasis Panel ZRG1 MDCN-A (03) M Oct. 28.

2011-Ad Hoc member of NOMD study section February 10-11.

2011-Ad Hoc Reviewer of Special Emphasis Panel ZRG1 MDCN-F (03) M July 13, 2011.

2011-Ad Hoc Reviewer of Special Emphasis Panel ZRG1 MDCN-E (03) S December 07, 2011.

2012-Ad Hoc Reviewer of ZRG1 EMNR-Q (50), P50 January 12, 2012

2012-Ad Hoc member of NOMD study section February 2-3

2012-Ad Hoc member of MDCN-T study section, June 14, 2012

2012- Ad Hoc member of NINR study section ‘Early detection and prevention of cognitive impairment (R01 grants), July 11, 2012.

2012-Ad Hoc member of NOMD study section October 10-11, 2012

2013-Ad Hoc member of MDCN study MDCN-R Neurotoxicity Special Emphasis Panel, April 11, 2013

2013-Ad Hoc member of NOMD study section June 13-14, 2013

2013-Ad Hoc Reviewer of NSD-B study section June 20-21, 2013 (Program Project Grants)

2013-Ad Hoc Reviewer of NIA-N study section July 19, 2013 (Program Project Grants)

2014-Ad Hoc Reviewer of R15 Grants (MDCN-R86) March 6-7, 2014

2018-Ad Hoc Reviewer of PAR-15-357, October 3, 2018

2018-Ad Hoc Reviewer of U19, October 26, 2018

2018-Ad Hoc Reviewer of R35, November 15, 2018

2019-Ad Hoc Reviewer of PAR-15-357, Feb 14, 2019

2019-Ad-hoc Reviewer of ZNS1 SRB-A (24) March 18, 2019

2019-Ad-hoc Reviewer of NIA Program Project Grants April 3, 2019

2019-Ad-hoc Reviewer of MDCN-C (03) M August 1, 2019

2019-Ad-hoc Reviewer of ZAG1-ZIJ-8 September 4, 2019

2019-Ad-hoc Reviewer of R15 Grants, October 31 to November 1, 2019

2019-Ad-hoc Reviewer of DoD grants (Programmatic Review II) September 12, 2019

2019-Ad-hoc Reviewer of DoD grants (Programmatic Review II) November 19, 2019

2020-Ad-hoc Reviewer of NIA – ZRG1 PSE-F (56) R, March 23, 2020

2020-Ad-hoc Reviewer of MDCN-C, April 23, 2020

2020-Ad-hoc Reviewer of ETTN-14, SEP July 28-29, 2020

 

 

Regular/Chartered Reviewer

2007-2011: Regular Member of VA Merit Review Study Section (Neurobiology-D)

2013-2019: Regular Member of Neural Oxidative Metabolism and Death Study Section [NOMD]

RESEARCH and OUTREACH SUPPORT

Ongoing

  1. R01 AG047812 grant Reddy, P.H. (P.I.) 05/15/2014-4/30/2021

‘Voltage-Dependent Anion Channel 1 and Neurodegeneration in Alzheimer’s Disease’. The overall objective of this grant application is to understand the role of voltage-dependent anion channel 1 in Alzheimer’s disease pathogenesis (RECEIVED 1.0 PERCENTILE SCORE – in the first submission). $2,171, 583.00 total award – No cost extension

 

  1. R01 NS105473 grant Reddy, P.H. (P.I). 09/25/2017-8/30/2022

‘Mitochondrial Fragmentation and Neurodegeneration in Huntington’s Disease’. The purpose of this application is to study the role of mutant-huntingtin induced mitochondrial fragmentation in Huntington’s disease (Received 6.0 percentile score – in the first submission). $2,000, 000 total award.

 

  1. R56 AG060767 grant Reddy, P.H. (P.I.) 07/17/2019-6/30/2021

Small Molecules as Therapeutic Drugs for Alzheimer’s Disease’. The purpose of this application is to study efficacies of mitochondria-targeted molecules in Alzheimer’s disease mouse models. Total Award $699.000

 

  1. R41AG060838 (STTR Phase I) Reddy, P.H. (PI) 09/30/2018-8/30/2021

‘Small Molecule Inhibitors as Therapeutic Targets in Alzheimer’s Disease’. The purpose of this application is to test the proof of principle of recently identified small molecule inhibitor – DDQ using Alzheimer’s disease mouse models. Total $250,000 total award

 

  1. R01 AG069333                                                 Reddy, P.H. (P.I.) 08/1/2020-07/30/2024

‘Mitochondrial Molecules as Therapeutic Drugs for Alzheimer’s Disease’. The purpose of this application is to study efficacies of mitochondria-targeted molecules in Alzheimer’s disease mouse models. $2.8M

 

  1. R56 AG066347-01A1 Reddy, P.H. (P.I.) 09/01/2020-08/30/2021

MicroRNA-455-3p and Alzheimer’s Disease. The purpose of this application is to study the protective and deleterious effects of MicroRNA-455-3p in Alzheimer’s Disease. Requested budget $600,000.

 

  1. K99AG065645-01A1 (Kumar S, P.I. and Reddy P.H. Primary Mentor) 07/01/2020-06/30/2025 NIH-NIA Synaptosomal MicroRNAs, Synaptic Damage and Cognitive Decline in Alzheimer’s Disease The purpose of this proposal is to investigate synaptic microRNAs in Alzheimer’s Disease. $939,170 requested.

 

Pending

 

  1. 1. PO1 AG73086 – PPG grant Reddy, P.H. (P.I) 07/10/2021-6/30/2026

‘mitochondria and Oxidative Stress in Aging’. The purpose of this Program Project Grant is to understand the role of mitochondria and oxidative stress in aging and Alzheimer’s disease. Requested budget $14.3M.

 

  1. RO1 AG074201 Reddy, P.H. (P.I.) 12/01/2020-11/30/2025

‘Healthy Lifestyle and Reduced Risk of Alzheimer’s’. The purpose of this proposal is to understand the beneficial effects of healthy lifestyle in reducing Alzheimer’s risk. Requested budget $3.4M

 

  1. R21 Reddy, P.H. (P.I.) 04/01/2021-03/30/2023

MicroRNA-5P-12969 and Ischemic Stroke. The purpose of this application is to development microRNA mouse models for Ischemic Stroke. Requested budget $420,000

 

  1. R41AG073056 (STTR Phase I) Reddy, P.H. (PI) 07/01/2021-6/30/2022

‘Small Molecule Inhibitor DDQ and Lifespan Extension’. The purpose of this application is to understand the protective properties of small molecule inhibitor – DDQ in extending lifespan in vitro and. In vivo. Total $200,000 total award

 

Completed

  1. SAGA (Sex and Gender) Reddy, P.H. – PI (contact) Reddy A.P. Co-PI.

Alzheimer’s Association (September 2016 – August 2019). The purpose of this application to study cellular changes in dorsal raphe (that regulates depression/anxiety) region of healthy brains from human and nonhuman primates. Total amount $250,000.

 

  1. R01 AG042178 Reddy, P. H. (PI) 9/30/2012-04/30/18

“ Dynamin-related Protein 1 and Mitochondrial Fragmentation in Alzheimer’s Disease”. The purpose of this application is to understand the role of Drp1 in mitochondrial fragmentation and neuronal damage in Alzheimer’s disease. $2,614,600.00 total award – Competing Renewal is in Progress

 

3.CH Foundation grant                                               Reddy, P.H. (PI) 01/01/2017 – 12/31/2017

‘Circulatory microRNAs As Peripheral Biomarkers – Frontiers Data’ The purpose of this application is to identify circulatory peripheral biomarkers for Alzheimer’s Disease. Total award is $50,000.00

 

  1. CH Foundation, 1-year grant (Yoon YS PI and Reddy PH – Co-Investigator) 2016-2017.

Title – Acupuncture is one option for tinnitus, one of the most common disorders in the US. The overall goal of this application is to understand the beneficial effects of acupuncture in Tinnitus patients. 2016-2017. $52,000.00 total award

 

  1. TTU-TTUHSC Presidential Collaborative Research Initiative Grant, 1 year (PIs: Hegde V and Reddy PH). 2015-2017 (extended). A novel tool to attenuate insulin resistance and associated risk of Alzheimer’s disease. The overall goal of this application is to understand the beneficial effects of AD36 against type 2 diabetes-induced AD pathogenesis. $25,000.00 total award

 

  1. T32-AG023477 Urbansky, H (PI) 07/01/2010-06/30/15

‘Neurobiology of Aging Training Grant’. The purpose of this training grant to train pre and postdoctotal scientists in the area of neurobiology/neuroscience of aging. Role (Co-Investigator). $2,187,000.00 total award

 

  1. Medical Research Foundation of Oregon Reddy, P.H. (P.I) 09/1/2012-8/31/13

Dynamin-Related Protein 1 and Mitochondrial Fragmentation in Alzheimer’s Disease’. The objective of this application is to understand the role of partial deficiency of dynamin-related protein 1 in mitochondrial fragmentation, dynamics, synaptic regeneration and neuronal function in Alzheimer’s disease. $40,000.00 total award.

 

  1. R01 AG028072 Reddy, P. H. (PI)                    07/01/07-06/30/12

NIA/NIH

“Abeta Toxicity, ROS and Mitochondrial Dysfunction in Aging/Alzheimer’s Disease”.   The objective of this proposal is to study the role of Amyloid beta in mitochondrial oxidative damage in Alzheimer’s disease. $1,877,500.00 total award

 

  1. Alzheimer’s Association IIRG Reddy, P. H. (PI) 12/01/09-11/30/12

‘Neuroprotection and Alzheimer’s Disease’. The objective of this study to determine neuroprotective role of mitochondrially targeted antioxidants in Alzheimer’s Disease. $200,000.00 total award

 

  1. Medivation Reddy, P.H. (PI) 09/01/09-08/31/11

‘Neuroprotective effects of Dimebon in Alzheimer’s disease’. The objective of this application is to study protective effects of Dimebon in Alzheimer’s disease neurons. $75,000.00 total award

 

  1. Vertex Pharmaceuticals Reddy, P.H. (PI)                     03/01/09-02/28/10

‘Mitochondrial-targeted antioxidant therapeutics in Multiple Sclerosis’. The objective of this project is to determine the neuroprotective effects of MitoQ in experimenal autoimmune encephalitis mouse model. $75,000.00

 

  1. NIA/NIH (R03 grant) Frerking, M. (PI) Reddy PH (co-PI- 07/01/07-06/31/09

“Synapse function in a mouse model of Alzheimer’s disease”. The objective of this proposal is to identify mechanisms underlying synaptic defects caused by accumulation of beta-amyloids, which is a major factor in the cognitive impairments in AD. Role (Co-PI). $154,000.00 total award

 

  1. KaloBios Pharmaceuticals 04/01/07-12/31/08

Anti-inflammatory effects of granulocyte colony stimulating factor in Alzheimer’s disease mouse models. The objective of this KaloBios Pharmaceuticals sponsored project was to study the anti-inflammatory effects of granulocyte colony stimulating factor (GMCSF) antibody in Alzheimer’s disease mouse models. $300,000.00 total award

 

  1. NIA/NIH (R03 grant) Reddy, PH (PI) 09/29/03 – 10/30/05

“Development of microarrays for Alzheimer’s disease mouse models”. The objective of this research proposal was to develop custom cDNA microarrays for AD transgenic mice. $75,000.000 total award

 

  1. Alzheimer’s Research Alliance of Oregon Reddy, PH (PI)             02/01/03 – 01/31/05

“Molecular and Cellular Mechanisms of Aging”. The objective of this project was to understand the molecular and cellular mechanisms of the aging process. $25,000.00 total award

 

  1. American Federation for Aging Research  Reddy, PH (PI)                      07/01/02 – 06/30/04

“Molecular analysis of the synaptopodin gene: A possible genetic link with late-onset Alzheimer’s disease”.  The aim of this project was to characterize one of the down-regulated genes, synaptopodin, in the brains of Alzheimer’s disease patients and in APP transgenic mice. $50,000.00 total award

 

  1. Alzheimer’s Research Alliance of Oregon Reddy, PH (PI)                          01/01/01 – 12/31/01

“Unraveling molecular events in Alzheimer’s disease mouse models using cDNA microarrays”

The objective of this project was to study gene expression profiles of transcripts in amyloid precursor protein transgenic mice. $25,000.00 total award

 

  1. Medical Research Foundation of Oregon Reddy, PH (PI)                       09/01/03 – 08/30/04

“Role of synaptic elements in Alzheimer’s disease”. The purpose of this project was to investigate synaptic damage in the brains of AD patients and AD transgenic mice. $30,000.00 total award

 

  1. Alzheimer’s Disease Center, NIA Grant P30 AG08017 Reddy, PH (PI)       04/01/01 – 03/30/02    “Early Neurodegenerative changes in Alzheimer’s disease mouse models using cDNA microarrays”

The purpose of this project was to verify amyloid precursor protein transgenic mice gene expression data using real-time quantitative RT-PCR and in situ hybridization analysis. $50,000.00 total award

 

  1. Huntington’s Disease Society of America Reddy PH (PI)                           01/01/99 – 12/31/00  “Pathomechanisms of Huntington’s Disease”. The purpose of this project was to study pathomechanisms of mutant huntingtin in Huntington’s disease progression. $30,000.00 total award

 

  1. Stopes Research Found, Galton Institute, London- Reddy PH (PI) 01/01/91-12/31/92

“Hemoglobin Disorders in a Tribal Population of Central India”. The purpose of this project was to study haemoglobin disorders in tribals of Madhya Pradesh, India. $10,000.00 total award

 

Patents

Patents are in progress –

 

  1. D-1289 (Aqua-soluble DDQ Promotes Healthy Aging and Delays Progression of Alzheimer’s Disease in Humans),
  2. D-1294 (Mitochondrial Division Inhibitor 1 for the Treatment of Alzheimer’s Disease),
  3. D-1417 (MicroRNA-455-3p as a Potential Peripheral Biomarker for Alzheimer’s Disease) and
  4. D-1535 (Identification of novel circulatory microRNA signatures linked to patients with Ischemic Stroke)

 

Publications in Reverse Chronological Order

 

Citations                      : 16,785 (Google Scholar Search dated December 4, 2020)          

H-index                       : 68     

i10-index                     : 130   

 

 

Google Scholar: https://scholar.google.com/citations?user=AfziV3YAAAAJ&hl=en

 

2020

 

  1. Dewanjee S, Vallamkondu J, Kalra RS, John A, Reddy PH and Kandimalla R (2020 Autophagy in the diabetic heart: a potential pharmaco-therapeutic target in diabetic cardiomyopathy, being reviewed in Ageing Research Reviews
  2. Ganj R and Reddy PH (2020) Impact of COVId-19 on Mitochondrial-based Immunity in Aging and Age-related Disease, being reviewed in Frontiers in Aging Neuroscience.
  3. Tran M and Reddy PH (2020) Defective Autophagy and Mitophagy in Aging and Alzheimer’s Disease, being reviewed in Frontiers in Neuroscience Neurodegeneration.
  4. John A, AliK and Reddy PH (2020) Alzheimer’s disease during COVID-19: Can Better Lifestyle Reduce Disease Progression?, being reviewed in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association
  5. Kumar S and Reddy PH (2020) Elevated levels of MicroRNA-455-3p in the cerebrospinal fluid of Alzheimer’s patients: a potential biomarker for Alzheimer’s disease, being reviewed in BBA Molecular Basis of Disease.
  6. Dewanjee S, John A, Vallamkondu V, Chakrabort P, Medala V, Sahu R, Kandimalla R and Reddy PH (2020). HDAC Epigenetic signatures: A New Generation Therapeutic Targets in Diabetes Mellitus, being reviewed in BBA Molecular Basis of Disease
  7. Shelidia S and Reddy PH (2020) Age-Related Chronic Diseases and Dementia in Texas: A Hispanics Focused Study, being reviewed in Journal Alzheimer’s Disease.
  8. Holder K and Reddy PH (2020) The COVID-19 Effect on Immune system and Mitochondrial Dynamics in Diabetes, Obesity and Dementia, Published in Neuroscientist.
  9. Pradeepkiran JA and Reddy PH (2020) Small molecules screening, pharmacophore modeling and molecular docking studies of pathogenic exon 1 HTT protein in Huntington’s disease, being reviewed in Biomolecules MDPI.
  10. Mullins CA, Gannaban RB, Khan MS, Shah H, Siddik MAB, Hegde VK, Reddy PH, Shin AC. Neural Underpinnings of Obesity: The Role of Oxidative Stress and Inflammation in the Brain. Antioxidants (Basel). 2020 Oct 20;9(10):1018.
  11. Bhatti JS, Thamarai K, Kandimalla R, Manczak M, Yin X, Kumar S, Vijayan M, Reddy PH. Mitochondria-Targeted Small Peptide, SS31 Ameliorates Diabetes Induced Mitochondrial Dynamics in Male TallyHO/JngJ Mice. Mol Neurobiol. 2020 Oct 7. doi: 10.1007/s12035-020-02142-7. Epub ahead of print. PMID: 33025510.
  12. Narasimhan M, Mahimainathan L, Reddy PH, Benamar K. GPR18-NAGly system in periaqueductal gray and chronic neuropathic pain. Biochim Biophys Acta Mol Basis Dis. 2020 Sep 17;1866(12):165974. doi: 10.1016/j.bbadis.2020.165974. Epub ahead of print. PMID: 32949767.
  13. Kumar S and Reddy PH (2020) The role of synaptic microRNA in Alzheimer’s disease, Published in Dec issue of BBA Molecular Basis of Disease.
  14. Bhatti, JS, Bhatti G, Reddy AP and Reddy PH (2020) Therapeutic Strategies in the Development of Anti-viral Drugs and Vaccines Against SARS-CoV-2 Infection, in press in Molecular Neurobiology DOI :1007/s12035-020-02074-2
  15. John A and Reddy PH (2020) Synaptic basis of Alzheimer’s disease: Focus on synaptic amyloid beta, P-tau and mitochondria, published online.
  16. Pradeepkiran JA and Reddy PH (2020) Defective Mitophagy in Alzheimer’s Disease, Published in Dec issue of Ageing Res Reviews.
  17. Vallamkondu J, John A, Wani WY, Ph.D. Ramadevi SP, Jella KK, Reddy PH and Kadimalla R. An overview of SARS-CoV-2 pathophysiology with a historical assessment of Coronaviruses in CNS diseases and a focus on therapeutic targets, BBA Molecular Basis of Disease, Jun 27;1866(10):165889.
  18. Shanmugam S, Redy D; Reddy PH, Guindon J, Narasimhan M and Benamar K (2020) Gene expression of endocannabinoid system in HIV-1-related neuropathic pain model, BBA Molecular Basis of Disease. Jul 3;1866(10):165891.
  19. Kandimalla R, John A, Abburi C, Vallamkondu J and Reddy PH (2020). Current Status of multiple drug molecules, and Vaccines: An update in SARS-CoV-2 therapeutics, in press in Molecular Neurobiology.
  20. John A, Kubosumi A and Reddy PH (2020) Mitochondrial MicroRNAs in Aging and Neurodegenerative Diseases. 2020 May 28;9(6):E1345. doi: 10.3390/cells9061345.
  21. Khan H, Reddy PH et al. (2020) Gender Differences in Prevalence of Myocardial Infarction in Rural West Texans. Journal of Public Health from Theory to Practice, in press.
  22. Vijayan M and Reddy PH (2020) Non-Coding RNAs Based Molecular Links in Type 2 Diabetes, Ischemic Stroke, and Vascular Dementia. J Alzheimers Dis. 2019;72(s1):S71-S79. doi: 10.3233/JAD-190808.
  23. Bhatti G, Reddy AP, Reddy PH and Bhatti J (2019) Lifestyle modifications and nutritional interventions in aging- associated cognitive decline and Alzheimer’s disease. Frontiers in Aging Neuroscience. Front Aging Neurosci. 2020 Jan 10;11:369. doi: 10.3389/fnagi.2019.00369. eCollection 2019.
  24. Pradeepkiran JA, Reddy AP, Yin X, Manczak M, Reddy PH. Protective Effects of BACE1 Inhibitory Ligand Molecules Against Amyloid Beta-Induced Synaptic and Mitochondrial Toxicities in Alzheimer’s Disease. Hum Mol Genet. 2020 Jan 1;29(1):49-69. doi: 10.1093/hmg/ddz227.
  25. Reddy PH. Current status of stem cell research: An editorial. Biochim Biophys Acta Mol Basis Dis. 2020 Jan 1;29(1):49-69. doi: 10.1093/hmg/ddz227.

[Epub ahead of print] PubMed PMID: 31862303.

  1. Mani C, Reddy PH, Palle K. DNA repair fidelity in stem cell maintenance, health, and disease. Biochim Biophys Acta Mol Basis Dis. 2020 Apr 1;1866(4):165444. doi: 10.1016/j.bbadis.2019.03.017.
  2. Kim Y, Gonzales JU, Reddy PH. An Investigation of Short-Term Longitudinal Associations Between Handgrip Strength and Cardiovascular Disease Biomarkers Among Middle-Aged to Older Adults: A Project FRONTIER Study. J Aging Phys Act. 2020 Jan 1;28(1):9-17. doi: 10.1123/japa.2018-0399.

2019

  1. Reddy PH. Lifestyle and Risk Factors of Dementia in Rural West Texas. JAlzheimers Dis. 2019;72(s1):S1-S10. doi: 10.3233/JAD-191280. PubMed PMID: 31884491.
  2. Khan H, Rafiq A, Shabaneh O, Gittner L and Reddy PH (2019) Current Issues in Chronic Diseases: A Focus on Dementia and Hypertension in Rural West Texans. J Alzheimers Dis. 2019;72(s1):S59-S69. doi: 10.3233/JAD-190893.
  3. Hegde V, Dhurandhar N and Reddy PH (2019) Hyperinsulinemia or Insulin Resistance. What Impacts the progression of Alzheimer’s Disease?. ?. J Alzheimers Dis. 2019;72(s1):S71-S79. doi: 10.3233/JAD-190808.
  4. Sawant N and Reddy PH (2019) Role of Phosphorylated Tau in Huntington’s Disease Progression, J Alzheimers Dis. 2019;72(s1):S177-S191. doi: 10.3233/JAD-190851.
  5. Hegde V, Vijayan M, Kumar S, Akheruzzaman M, Sawant N, Dhurandhar NV, Reddy PH. Adenovirus 36 improves glycemic control and markers of Alzheimer’s disease pathogenesis. Biochim Biophys Acta Mol Basis Dis. 2019; 1865(11):165531.

doi: 10.1016/j.bbadis.2019.08.007.

  1. Vijayan M, Alamri FF, Al Shoyaib A, Karamyan VT, Reddy PH. Novel miRNA PC-5P-12969 in Ischemic Stroke. Mol Neurobiol. 2019; 56(10):6976-6985.

doi: 10.1007/s12035-019-1562-x.

  1. Kumar S, Reddy PH. A New Discovery of MicroRNA-455-3p in Alzheimer’s Disease. J Alzheimers Dis. 2019. doi: 10.3233/JAD-190583.
  2. Kumar S, Reddy AP, Yin X, Reddy PH. Novel MicroRNA-455-3p and its protective effects against abnormal APP processing and amyloid beta toxicity in Alzheimer’s disease. Biochim Biophys Acta Mol Basis Dis. 2019; 1865(9):2428-2440.

doi: 10.1016/j.bbadis.2019.06.006.

  1. Tamarai K, Bhatti JS, Reddy PH. Molecular and cellular bases of diabetes: Focus on type 2 diabetes mouse model-TallyHo. Biochim Biophys Acta Mol Basis Dis. 2019;1865(9):2276-2284. doi: 10.1016/j.bbadis.2019.05.004.
  2. Oliver D, Reddy PH. Dynamics of Dynamin-Related Protein 1 in Alzheimer’s Disease and Other Neurodegenerative Diseases. Cells. 2019; 8(9). pii: E961.

doi: 10.3390/cells8090961.

  1. Ramasubramanian B, Reddy PH. Are TallyHo Mice A True Mouse Model for Type 2 Diabetes and Alzheimer’s Disease? J Alzheimers Dis. 2019.

doi: 10.3233/JAD-190613.

  1. Hegde V, Vijayan M, Kumar S, Akheruzzaman M, Sawant N, Dhurandhar NV, Reddy PH. Adenovirus 36 improves glycemic control and markers of Alzheimer’s disease pathogenesis. Biochim Biophys Acta Mol Basis Dis. 2019; 1865(11):165531.

doi: 10.1016/j.bbadis.2019.08.007

  1. Gamage S, Peddibhotla S, Reddy PH, Dhurandhar NV, Hegde V. Improvement in Glycemic Control in Mice of Different Age Groups. Exp Clin Endocrinol Diabetes. 2019. doi: 10.1055/a-0961-7804.
  2. George EK, Reddy PH. Can Healthy Diets, Regular Exercise, and Better Lifestyle Delay the Progression of Dementia in Elderly Individuals? J Alzheimers Dis. 2019.

doi: 10.3233/JAD-190232.

  1. Reddy PH, Oliver DM. Amyloid Beta and Phosphorylated Tau-Induced Defective Autophagy and Mitophagy in Alzheimer’s Disease. Cells. 2019;8(5). pii: E488.

doi: 10.3390/cells8050488.

  1. Reddy PH, Swerdlow RH, Culberson J, Kang D, Mitchell TL, Smith Q, Suneja S, Ory MG, Kumar S, Vijayan M, Morsy A, Arandia G, Lawrence JJ, George E, Oliver D, Pradeepkiran JA, Yin X, Reddy AP, Manczak M, Cengiz P, Karamyan VT, Kandimalla R, Kuruva CS, Willms J, Ramasubramanian B, Sawant N, Burugu D, Boles AN, Lopez V, Carrasco R, Aguirre C, Thompson S, Blackmon J, Ament C, Wang R, Stephens ER, Hoang B, Bass K, Trippier PC, Hornback C, Kottapalli P, Kottapalli KR; Center Biotechnology and Genetics Core Facility, Oddo S. Current Status of Healthy Aging and Dementia Research: A Symposium Summary. J Alzheimers Dis. 2019.

doi: 10.3233/JAD-190252.

  1. Amakiri N, Kubosumi A, Tran J, Reddy PH. Amyloid Beta and MicroRNAs in Alzheimer’s Disease. Front Neurosci. 2019; 13:430. doi: 10.3389/fnins.2019.00430.
  2. Rahman MFA, Reddy PH, Paul MC, Das S, Dhar A, Baharom MF, Latiff AA, Rusdi MFM, Wang P, Dimyati K, Harun SW. Titanium dioxide fiber saturable absorber for Q-switched fiber laser generation in the 1-micrometer region. Appl Opt. 2019;58(13):3495-3500. doi: 10.1364/AO.58.003495.
  3. Vijayan M, Alamri FF, Al Shoyaib A, Karamyan VT, Reddy PH. Novel miRNA PC-5P-12969 in Ischemic Stroke. Mol Neurobiol. 2019;56(10):6976-6985.

doi: 10.1007/s12035-019-1562-x.

  1. Oliver DMA, Reddy PH. Molecular Basis of Alzheimer’s Disease: Focus on Mitochondria. J Alzheimers Dis. 2019. doi: 10.3233/JAD-190048.
  2. Pradeepkiran JA, Reddy PH. Structure Based Design and Molecular Docking Studies for Phosphorylated Tau Inhibitors in Alzheimer’s Disease. Cells. 2019;8(3). pii: E260.

doi: 10.3390/cells8030260.

  1. Oliver DMA, Reddy PH. Small molecules as therapeutic drugs for Alzheimer’s disease. Mol Cell Neurosci. 2019;96:47-62. doi: 10.1016/j.mcn.2019.03.001.
  2. Gamage S, Reddy PH, Dhurandhar NV, Hegde V. Potential role of E4orf1 protein in aging-associated impairment in glycemic control. J Diabetes Complications. 2019;33(3):261-265. doi: 10.1016/j.jdiacomp.2018.11.006.
  3. Vallamkondu J, Corgiat EB, Buchaiah G, Kandimalla R, Reddy PH. Liquid Crystals: A Novel Approach for Cancer Detection and Treatment. Cancers (Basel). 2018;10(11). pii: E462. doi: 10.3390/cancers10110462.
  4. Pradeepkiran JA, Reddy AP, Reddy PH. Pharmacophore-based models for therapeutic drugs against phosphorylated tau in Alzheimer’s disease. Drug Discov Today. 2019 24(2):616-623. doi: 10.1016/j.drudis.2018.11.005.
  5. Manczak M, Kandimalla R, Yin X, Reddy PH. Mitochondrial division inhibitor 1 reduces dynamin-related protein 1 and mitochondrial fission activity. Hum Mol Genet. 2019; 28(2):177-199. doi: 10.1093/hmg/ddy335.

 

2018

  1. Vijayan M, Kumar S, Yin X, Zafer D, Chanana V, Cengiz P, Reddy PH. Identification of novel circulatory microRNA signatures linked to patients with ischemic stroke. Hum Mol Genet. 2018; 27(13):2318-2329. doi: 10.1093/hmg/ddy136.
  2. Reddy PH, Yin X, Manczak M, Kumar S, Pradeepkiran JA, Vijayan M, Reddy AP. Mutant APP and amyloid beta-induced defective autophagy, mitophagy, mitochondrial structural and functional changes and synaptic damage in hippocampal neurons from Alzheimer’s disease. Hum Mol Genet. 2018; 27(14):2502-2516.

doi: 10.1093/hmg/ddy335.

  1. Kumar S, Reddy PH. MicroRNA-455-3p as a Potential Biomarker for Alzheimer’s Disease: An Update. Front Aging Neurosci. 2018;10:41. doi: 10.3389/fnagi.2018.00041.
  2. Manczak M, Yin X, Kandimalla R, Reddy PH. Hippocampal mutant APP and amyloid beta Induced Cognitive Decline, Dendritic Spine Loss, Defective Autophagy & Mitophagy and Mitochondrial Abnormalities in a Mouse Model of Alzheimer’s Disease. Hum Mol Genet. 2018; 27(8):1332-1342. doi: 10.1093/hmg/ddy042.
  3. Reddy PH, Manczak M, Yin X, Reddy AP. Synergistic Protective Effects of Mitochondrial division inhibitor and mitochondria-targeted antioxidant peptide SS31 in Alzheimer’s Disease. J Alzheimers Dis, 2018; 62, 1549-1565. doi: 10.3233/JAD-170988.
  4. Reddy PH. Can Diabetes Be Controlled by Lifestyle Activities? Curr Res Diabetes Obes J. 1(4). pii: 555568. PubMed PMID: 29399663; PubMed Central PMCID: PMC5792082.
  5. Reddy PH, Manczak M, Yin X, Grady MC, Mitchell A, Tonk S, Kuruva CS, Bhatti JS, Kandimalla R, Vijayan M, Kumar S, Wang R, Pradeepkiran JA, Ogunmokun G, Thamarai K, Quesada K,Boles A, Reddy AP. Protective Effects of Indian Spice Curcumin Against Amyloid-β in Alzheimer’s Disease. J Alzheimers Dis. 2018; 61, 843-866. doi: 10.3233/JAD-170512.
  6. Kandimalla R, Manczak M, Yin X, Wang R, Reddy PH. Hippocampal Phosphorylated Tau Induced Cognitive Decline, Dendritic Spine Loss and Mitochondrial Abnormalities in a Mouse Model of Alzheimer’s Disease. Hum Mol Genet. 2018; 27, 30-40.

doi: 10.1093/hmg/ddx381.

 

2017

  1. Kumar S, Vijayan M, Reddy PH. MicroRNA-455-3p as a potential peripheral biomarker for Alzheimer’s disease. Hum Mol Genet. 2017; 26, 3808-3822.

doi: 10.1093/hmg/ddx267.

  1. Kuruva CS, Manczak M, Yin X, Okunmokun G, Reddy AP, Reddy PH. Aqua-Soluble DDQ Reduces the levels of Drp1 and Aβ and Inhibits Abnormal Interactions between Aβ and Drp1 and Protects Alzheimer’s Disease Neurons From Aβ- and Drp1-induced Mitochondrial and Synaptic Toxicities Hum Mol Genet. 201726, 3375-3395.

doi: 10.1093/hmg/ddx226. (Figure 1 was selected for cover image).

  1. Rajmohan R, Anderson RC, Fang D, Meyer AG, Laengvejkal P, Julayanont P, Hannabas G, Linton K, Culberson J, Khan H, De Toledo J, Reddy PH, O’Boyle MW. Lower Activation in Frontal Cortex and Posterior Cingulate Cortex Observed during Sex Determination Test in Early-Stage Dementia of the Alzheimer Type. Front Aging Neurosci. 2017; 9:156. doi: 10.3389/fnagi.2017.00156.
  2. Reddy PH, Manczak M, Kandimalla R. Mitochondria-targeted small molecule SS31: a potential candidate for the treatment of Alzheimer’s disease. Hum Mol Genet. 2017; 26(8):1597. doi: 10.1093/hmg/ddx129.
  3. Reddy PH. A Critical Assessment of Research on Neurotransmitters in Alzheimer’s Disease. J Alzheimers Dis. 2017; 57, 969-974. doi: 10.3233/JAD-170256.
  4. Reddy PH, Manczak M, Yin X. Mitochondria-Division Inhibitor 1 Protects Against Amyloid-β induced Mitochondrial Fragmentation and Synaptic Damage in Alzheimer’s  J Alzheimers Dis. 2017; 58, 147-162. doi: 10.3233/JAD-170051.
  5. Rajmohan R, Anderson RC, Fang D, Meyer AG, Laengvejkal P, Julayanont P, Hannabas G, Linton K, Culberson J, Khan HM, De Toledo J, Reddy PH, O’Boyle M. White Matter Deterioration May Foreshadow Impairment of Emotional Valence Determination in Early-Stage Dementia of the Alzheimer Type. Front Aging Neurosci. 2017; 9:37.

doi: 10.3389/fnagi.2017.00037.

  1. Chung E, Joiner HE, Skelton T, Looten KD, Manczak M, Reddy PH. Maternal exercise upregulates mitochondrial gene expression and increases enzyme activity of fetal mouse hearts. Physiol Rep. 2017; 5(5). pii: e13184. doi: 10.14814/phy2.13184.
  2. Reddy PH (2017) Preface. Prog Mol Biol Transl Sci. 146:xvii-xx.

doi: 10.1016/S1877 1173(17)30028-5.

  1. Vijayan M, Kumar S, Bhatti JS, Reddy PH. Molecular Links and Biomarkers of Stroke, Vascular Dementia, and Alzheimer’s Disease. Prog Mol Biol Transl Sci. 2017;146:95-126. doi: 10.1016/bs.pmbts.2016.12.014.
  2. Kumar S, Vijayan M, Bhatti JS, Reddy PH. MicroRNAs as Peripheral Biomarkers in Aging and Age-Related Diseases. Prog Mol Biol Transl Sci. 2017; 146, 47-94.

doi: 10.1016/bs.pmbts.2016.12.013.

  1. Reddy AP, Reddy PH. Mitochondria-Targeted Molecules as Potential Drugs to Treat Patients With Alzheimer’s Disease. Prog Mol Biol Transl Sci. 2017; 146, 173-201.

doi: 10.1016/bs.pmbts.2016.12.010.

  1. Bhatti JS, Kumar S, Vijayan M, Bhatti GK, Reddy PH. Therapeutic Strategies for Mitochondrial Dysfunction and Oxidative Stress in Age-Related Metabolic Disorders. Prog Mol Biol Transl Sci. 2017; 146,13-46. doi: 10.1016/bs.pmbts.2016.12.012.
  2. Reddy PH, Williams J, Smith F, Bhatti JS, Kumar S, Vijayan M, Kandimalla R, Kuruva CS, Wang R, Manczak M, Yin X, Reddy AP. MicroRNAs, Aging, Cellular Senescence, and Alzheimer’s Disease. Prog Mol Biol Transl Sci. 2017; 146, 127-171.

doi: 10.1016/bs.pmbts.2016.12.009.

  1. Reddy PH. Editorial of the article. Biochim Biophys Acta. 2017; 1863, 1023-1025.

DOI: 10.1016/j.bbadis.2017.02.010.

  1. Kandimalla R, Reddy PH. Therapeutics of Neurotransmitters in Alzheimer’s Disease. J Alzheimers Dis. 2017; 57, 1049-1069. doi: 10.3233/JAD-161118.
  2. Reddy PH, Manczak M, Kandimalla R. Mitochondria-targeted small molecule SS31: a potential candidate for the treatment of Alzheimer’s disease. Hum Mol Genet. 2017; 26, 1483-1496. doi: 10.1093/hmg/ddx052.
  3. Kandimalla R, Manczak M, Fry D, Suneetha Y, Sesaki H, Reddy PH. Reduced Dynamin-related Protein 1 Protects Against Phosphorylated Tau-induced Mitochondrial Dysfunction and Synaptic Damage in Alzheimer’s Disease. Hum Mol Genet. 2016; 25, 4881-4897.
  4. Boles A, Kandimalla R, Reddy PH. Dynamics of diabetes and obesity: Epidemiological perspective. Biochim Biophys Acta. 2017; 1863, 1026-1036.

doi: 10.1016/j.bbadis.2017.01.016.

  1. Khan HMR, Mende S, Rafiq A, Gabbidon K, Reddy PH. Methods needed to measure predictive accuracy: A study of diabetic patients. Biochim Biophys Acta. 2017; 1863, 1046-1053. doi: 10.1016/j.bbadis.2017.01.007.
  2. Williams J, Smith F, Kumar S, Vijayan M, Reddy PH. Are microRNAs true sensors of ageing and cellular senescence? Ageing Res Rev. 2017; 35, 350-363.

doi: 10.1016/j.arr.2016.11.008.

  1. Bhatti JS, Bhatti GK, Reddy PH. Mitochondrial dysfunction and oxidative stress in metabolic disorders – A step towards mitochondria based therapeutic strategies. Biochim Biophys Acta. 2017; 1863, 1066-1077. doi: 10.1016/j.bbadis.2016.11.010.
  2. Kuruva CS, Reddy PH. Amyloid beta modulators and neuroprotection in Alzheimer’s disease: A critical appraisal. Drug Discov Today. 2017; 22, 223-233.

doi: 10.1016/j.drudis.2016.10.010.

 

2016

  1. Manczak M, Kandimalla R, Fry D, Sesaki H, Reddy PH. Protective effects of reduced dynamin-related protein 1 against amyloid beta-induced mitochondrial dysfunction and synaptic damage in Alzheimer’s disease. Hum Mol Genet. 2016; 25, 5148-5166.

doi: 10.1093/hmg/ddw330.

  1. Wang R, Reddy PH. Role of Glutamate and NMDA Receptors in Alzheimer’s Disease. J Alzheimers Dis. 2017; 57, 1041-1048. doi: 10.3233/JAD-160763.
  2. Kandimalla R, Thirumala V, Reddy PH. Is Alzheimer’s disease a Type 3 Diabetes? A critical appraisal. Biochim Biophys Acta. 2017; 1863(5):1078-1089.

doi: 10.1016/j.bbadis.2016.08.018.

  1. Rajmohan R, Reddy PH. Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer’s disease Neurons. J Alzheimers Dis. 2017; 57, 975-999. doi: 10.3233/JAD-160612.
  2. Vijayan M, Reddy PH. Stroke, Vascular Dementia, and Alzheimer’s Disease: Molecular Links. J Alzheimers Dis. 2016; 54, 427-443. doi: 10.3233/JAD-160527.
  3. Reddy PH, Tonk S, Kumar S, Vijayan M, Kandimalla R, Kuruva CS, Reddy AP. A critical evaluation of neuroprotective and neurodegenerative MicroRNAs in Alzheimer’s disease. Biochem Biophys Res Commun. 2017; 483, 1156-1165.

doi: 10.1016/j.bbrc.2016.08.067.

  1. Reddy PH, Manczak M, Yin X, Grady MC, Mitchell A, Kandimalla R, Kuruva CS. Protective effects of a natural product, curcumin, against amyloid β induced mitochondrial and synaptic toxicities in Alzheimer’s disease. J Investig Med. 2016; 64(8):1220-1234. DOI: 10.1136/jim-2016-000240.
  2. Vijayan M, Reddy PH. Peripheral biomarkers of stroke: Focus on circulatory microRNAs. Biochim Biophys Acta. 2016; 1862, 1984-1993.

doi: 10.1016/j.bbadis.2016.08.003.

  1. Kumar S, Reddy PH. Are circulating microRNAs peripheral biomarkers for Alzheimer’s disease? BiochimBiophys Acta. 2016; 1862, 1617-1627.

doi: 10.1016/j.bbadis.2016.06.001.

  1. Wani WY, Kandimalla RJ, Sharma DR, Kaushal A, Ruban A, Sunkaria A, Vallamkondu J, Chiarugi A, Reddy PH, Gill KD. Cell cycle activation in p21 dependent pathway: An alternative mechanism of organophosphate induced dopaminergic neurodegeneration. Biochim Biophys Acta. 2017; 1863, 1858-1866. doi: 10.1016/j.bbadis.2016.05.014.
  2. Boles AN, Khan H Lenzmeier TA, Molinar-Lopez VA, Ament JC, TeBrink KL, Stonum K, Gonzales RM, Reddy PH. Impact of Exercise and Education in Adults of Lubbock, Texas: Implications for Better Lifestyle Front Aging Neurosci. 2016;8:85.

doi: 10.3389/fnagi.2016.00085.

  1. Pugazhenthi S, Qin L, Reddy PH. Common neurodegenerative pathways in obesity, diabetes and Alzheimer’s disease. Biochim Biophys Acta. 2017; 1863, 1037-1045.

doi: 10.1016/j.bbadis.2016.04.017.

  1. Yin X, Manczak M, Reddy PH. Mitochondria-targeted molecules MitoQ and SS31 reduce mutant huntingtin-induced mitochondrial toxicity and synaptic damage in Huntington’s disease. Hum Mol 2016; 25, 1739-1753. doi: 10.1093/hmg/ddw045.
  2. Kandimalla R, Reddy PH.Multiple faces of Dynamin-related protein 1 and its role in Alzheimer’s disease pathogenesis. BBA Molecular Basis of Disease. 2016; 4, 814–828. doi: 10.1016/j.bbadis.2015.12.018.

2015

  1. Blackmon J, Boles AN, Reddy PH. Garrison Institute on Aging – Lubbock Retired and Senior Volunteer Program (RSVP) Provides Services to South Plains, Texas. Frontiers in Aging            Neuroscience 2015 Dec 8;7:215. doi: 10.3389/fnagi.2015.00215.
  2. Manczak M, Reddy PH. Mitochondrial Division Inhibitor 1 Protects Against Mutant Huntingtin-induced Abnormal Mitochondrial Dynamics and Neuronal Damage in Huntington’s Disease-Hum Mol Genet 2015; 24, 7308-7325.

doi: 10.3389/fnagi.2015.00215.

  1. Reddy PH, Blackmon J, Molinar-Lopez V, Ament C, Manczak M, Kandimalla R, Yin X, Pandey AK, Kuruva CS, Wang R, Fry DR, Osborn C, Stonum K, Quesada K, Gonzales R and Boles Garrison Institute on Aging – A New Hope for Elderly Individuals and Patients with Alzheimer’s Disease. J Alzheimers Dis 2015; 48, 547-555.

doi: 10.3233/JAD-150490.

  1. Roy M, Reddy PH, Iijima M, Sesaki H. Mitochondrial division and fusion in metabolism. Curr Opin Cell Biol. 2015; 33,111-118. doi: 10.1016/j.ceb.2015.02.001.

2014

  1. Advani MJ, Rajagopalan M, Reddy PH. Calmodulin-like protein from M. tuberculosis H37Rv is required during infection. Sci Rep. 2014; 4:6861. doi: 10.1038/srep06861.
  2. Reddy PH. Editorial of a special issue – ‘Misfolded Proteins, Mitochondrial Dysfunction and Neurodegenerative Diseases, Biochim Biophys Acta, 2014; 1842, 1167.

doi: 10.1038/srep06861.

  1. Reddy PH. Increased mitochondrial fission and neuronal dysfunction in Huntington’s disease: implications for molecular inhibitors of excessive mitochondrial fission. Drug Discov Today. 2014; 19, 951-5. doi: 10.1016/j.drudis.2014.03.020.
  2. Reddy PH. Inhibitors of mitochondrial fission as a therapeutic strategy for diseases with oxidative stress and mitochondrial dysfunction. J Alzheimers Dis. 2014;40, 245-56.

doi: 10.3233/JAD-132060.

 

2013

  1. Manczak M, Reddy PH. RNA silencing of genes involved in Alzheimer’s disease enhances mitochondrial function and synaptic activity. Biochim Biophys Acta. 2013; 1832, 2368-78. doi: 10.1016/j.bbadis.2013.09.008.
  2. Mao P, Manczak M, Shirendeb UP, Reddy PH. MitoQ, a mitochondria-targeted antioxidant, delays disease progression and alleviates pathogenesis in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis. Biochim Biophys Acta. 2013; 1832, 2322-31. doi: 10.1016/j.bbadis.2013.09.005.
  3. Reddy PH. Amyloid beta-induced glycogen synthase kinase 3β phosphorylated VDAC1 in Alzheimer’s disease: implications for synaptic dysfunction and neuronal damage. Biochim Biophys Acta. 2013; 1832, 1913-21. doi: 10.1016/j.bbadis.2013.06.012.
  4. Reddy PH. Is the mitochondrial outermembrane protein VDAC1 therapeutic target for Alzheimer’s disease? Biochim Biophys Acta. 2013; 1832, 67-75.

doi: 10.1016/j.bbadis.2012.09.003.

  1. Manczak M, Sheiko T, Craigen WJ, Reddy PH. Reduced VDAC1 protects against Alzheimer’s disease, mitochondria, and synaptic deficiencies. J Alzheimers Dis. 2013;37, 679-90. doi: 10.3233/JAD-130761.
  2. Manczak M, Reddy PH. Abnormal interaction of oligomeric amyloid-β with phosphorylated tau: implications to synaptic dysfunction and neuronal damage. J Alzheimers Dis. 2013;36, 285-95. doi: 10.3233/JAD-130275.
  3. Mao P, Meshul CK, Thuillier P, Reddy PH. Neurotransmitter CART as a New Therapeutic Candidate for Parkinson’s Disease. Pharmaceuticals (Basel). 2013; 6,108-23. doi: 10.3390/ph6010108.

 

2012

  1. Manczak M, Reddy PH. Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer’s disease. Hum Mol Genet. 2012; 21, 5131-46. doi: 10.1093/hmg/dds360.
  2. Mao P, Manczak M, Calkins MJ, Truong Q, Reddy TP, Reddy AP, Shirendeb U, Lo HH, Rabinovitch PS, Reddy PH. Mitochondria-targeted catalase reduces abnormal APP processing, amyloid β production and BACE1 in a mouse model of Alzheimer’s disease: implications for neuroprotection and lifespan extension. Hum Mol Genet. 2012;21, 2973-90. doi: 10.1093/hmg/dds128.
  3. Manczak M, Sesaki H, Kageyama Y, Reddy PH. Dynamin-related protein 1 heterozygote knockout mice do not have synaptic and mitochondrial deficiencies. Biochim Biophys Acta. 2012; 1822, 862-74. doi: 10.1016/j.bbadis.2012.02.017.
  4. Manczak M, Reddy PH. Abnormal interaction between the mitochondrial fission protein Drp1 and hyperphosphorylated tau in Alzheimer’s disease neurons: implications for mitochondrial dysfunction and neuronal damage. Hum Mol Genet. 2012; 21, 2538-47. doi: 10.1093/hmg/dds072.
  5. Kageyama Y, Zhang Z, Roda R, Fukaya M, Wakabayashi J, Wakabayashi N, Kensler TW, Reddy PH, Iijima M, Sesaki H. Mitochondrial division ensures the survival of postmitotic neurons by suppressing oxidative damage. J Cell Biol. 2012;197, 535-51.

doi: 10.1083/jcb.201110034.

  1. Reddy PH, Tripathi R, Troung Q, Tirumala K, Reddy TP, Anekonda V, Shirendeb UP, Calkins MJ, Reddy AP, Mao P, Manczak M. Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer’s disease: implications to mitochondria-targeted antioxidant therapeutics. Biochim Biophys Acta. 2012; 1822, 639-49. doi: 10.1016/j.bbadis.2011.10.011.
  2. Reddy PH. Editorial of a special issue. Current status of therapeutics and preventive measures for patients with thalassaemia and sickle cell disease. Cardiovasc Hematol Agents Med Chem. 2012; 10, 2. DOI : 10.2174/187152512799201154
  3. Reddy PH, Shirendeb UP. Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington’s disease. Biochim Biophys Acta. 2012; 1822, 101-10.

doi: 10.1016/j.bbadis.2011.10.016.

  1. Mao P, Gallagher P, Nedungadi S, Manczak M, Shirendeb UP, Kohama SG, Ferguson B, Park BS, Reddy PH. Mitochondrial DNA deletions and differential mitochondrial DNA content in Rhesus monkeys: implications for aging. Biochim Biophys Acta. 2012; 1822, 111-9. doi: 10.1016/j.bbadis.2011.10.014.
  2. Shirendeb UP, Calkins MJ, Manczak M, Anekonda V, Dufour B, McBride JL, Mao P, Reddy PH. Mutant huntingtin’s interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington’s disease. Hum Mol Genet. 2012; 21, 406-20. doi: 10.1093/hmg/ddr475.
  3. Calkins MJ, Manczak M, Reddy PH. Mitochondria-Targeted Antioxidant SS31 Prevents Amyloid Beta-Induced Mitochondrial Abnormalities and Synaptic Degeneration in Alzheimer’s Disease. Pharmaceuticals (Basel). 2012; 5, 1103-19.

doi: 10.3390/ph5101103.

  1. Mao P, Meshul CK, Thuillier P, Goldberg NR, Reddy PH. CART peptide is a potential endogenous antioxidant and preferentially localized in mitochondria. PLoS One. 2012; 7(1):e29343. doi: 10.1371/journal.pone.0029343.
  2. Mao P, Reddy PH. Aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in Alzheimer’s disease: implications for early intervention and therapeutics. Biochim Biophys Acta. 2011; 1812, 1359-70. doi:10.1016/j.bbadis.2011.08.005.
  3. Reddy PH. Abnormal tau, mitochondrial dysfunction, impaired axonal transport of mitochondria, and synaptic deprivation in Alzheimer’s disease. Brain Res. 2011;1415, 136-48. doi: 10.1016/j.brainres.2011.07.052.
  4. Calkins MJ, Reddy PH. Assessment of newly synthesized mitochondrial DNA using BrdU labeling in primary neurons from Alzheimer’s disease mice: Implications for impaired mitochondrial biogenesis and synaptic damage. Biochim Biophys Acta. 2011;1812, 1182-9. doi: 10.1016/j.bbadis.2011.04.006.
  5. Ricoy UM, Mao P, Manczak M, Reddy PH, Frerking ME. A transgenic mouse model for Alzheimer’s disease has impaired synaptic gain but normal synaptic dynamics. Neurosci Lett. 2011; 500, 212-5. doi: 10.1016/j.neulet.2011.06.043.

2011

  1. Manczak M, Calkins MJ, Reddy PH. Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer’s disease: implications for neuronal damage. Hum Mol Genet. 2011; 20, 2495-509. doi: 10.1093/hmg/ddr139.
  2. Reddy PH, Reddy TP, Manczak M, Calkins MJ, Shirendeb U, Mao P. Dynamin-related protein 1 and mitochondrial fragmentation in neurodegenerative diseases. Brain Res Rev. 2011 Jun 24;67(1-2):103-18. doi: 10.1016/j.brainresrev.2010.11.004.
  3. Reddy PH, Reddy TP. Mitochondria as a therapeutic target for aging and neurodegenerative diseases. Curr Alzheimer Res. 2011; 8, 393-409. DOI: 10.2174/156720511795745401.
  4. Calkins MJ, Reddy PH. Amyloid beta impairs mitochondrial anterograde transport and degenerates synapses in Alzheimer’s disease neurons. Biochim Biophys Acta. 2011; 1812, 507-13. doi: 10.1016/j.bbadis.2011.01.007.
  5. Shirendeb U, Reddy AP, Manczak M, Calkins MJ, Mao P, Tagle DA, Reddy PH. Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington’s disease: implications for selective neuronal damage. Hum Mol Genet. 2011; 20, 1438-55. doi: 10.1093/hmg/ddr024.
  6. Reddy PH. Mitochondrial Dysfunction and Oxidative Stress in Asthma: Implications for Mitochondria-Targeted Antioxidant Therapeutics. Pharmaceuticals (Basel). 2011; 4, 429-456. PMID: 21461182.
  7. Reddy TP, Manczak M, Calkins MJ, Mao P, Reddy AP, Shirendeb U, Park B, Reddy PH. Toxicity of neurons treated with herbicides and neuroprotection by mitochondria-targeted antioxidant SS31. Int J Environ Res Public Health. 2011; 8, 203-21.

doi: 10.3390/ijerph8010203.

  1. Calkins MJ, Manczak M, Mao P, Shirendeb U, Reddy PH. Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer’s disease. Hum Mol Genet. 2011 Dec 1;20(23):4515-29. doi: 10.1093/hmg/ddr381.

 

2010

  1. Mao P, Reddy PH. Is multiple sclerosis a mitochondrial disease?. Biochim Biophys Acta. 2010 Jan;1802(1):66-79. doi: 10.1016/j.bbadis.2009.07.002.
  2. Manczak M, Mao P, Calkins MJ, Cornea A, Reddy AP, Murphy MP, Szeto HH, Park B, Reddy PH. Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer’s disease neurons. J Alzheimers Dis. 2010;20 Suppl 2:S609-31.

doi: 10.3233/JAD-2010-100564.

  1. Reddy PH, Manczak M, Mao P, Calkins MJ, Reddy AP, Shirendeb U. Amyloid-beta and mitochondria in aging and Alzheimer’s disease: implications for synaptic damage and cognitive decline. J Alzheimers Dis. 2010;20 Suppl 2:S499-512.

doi: 10.3233/JAD-2010-100504.

 

2009

  1. Reddy PH, Manczak M, Zhao W, Nakamura K, Bebbington C, Yarranton G, Mao P. Granulocyte-macrophage colony-stimulating factor antibody suppresses microglial activity: implications for anti-inflammatory effects in Alzheimer’s disease and multiple sclerosis. J Neurochem. 2009;111, 1514-28. doi: 10.1111/j.1471-4159.2009.06432.x.
  2. Manczak M, Mao P, Nakamura K, Bebbington C, Park B, Reddy PH. Neutralization of granulocyte macrophage colony-stimulating factor decreases amyloid beta 1-42 and suppresses microglial activity in a transgenic mouse model of Alzheimer’s disease. Hum Mol Genet. 2009; 18(20):3876-93. doi: 10.1093/hmg/ddp331.
  3. Reddy PH. Role of mitochondria in neurodegenerative diseases: mitochondria as a therapeutic target in Alzheimer’s disease. CNS Spectr. 2009; 14(8 Suppl 7):8-13; discussion 16-8. DOI: 10.1017/s1092852900024901.
  4. Reddy PH. Amyloid beta, mitochondrial structural and functional dynamics in Alzheimer’s disease. Exp Neurol. 2009; 218,286-92.

doi: 10.1016/j.expneurol.2009.03.042.

  1. Reddy PH, Mao P, Manczak M. Mitochondrial structural and functional dynamics in Huntington’s disease. Brain Res Rev. 2009; 61, 33-48.

doi: 10.1016/j.brainresrev.2009.04.001.

 

2008

  1. Reddy PH, Beal MF. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer’s disease. Trends Mol Med. 2008; 14, 45-53. doi: 10.1016/j.molmed.2007.
  2. Reddy PH. Mitochondrial medicine for aging and neurodegenerative diseases. Neuromolecular Med. 2008;10(4):291-315. doi: 10.1007/s12017-008-8044-z.

 

 

2007

  1. Reddy PH. Mitochondrial dysfunction in aging and Alzheimer’s disease: strategies to protect neurons. Antioxid Redox Signal. 2007; 9(10):1647-58.

DOI: 10.1089/ars.2007.1754.

 

2006

  1. Reddy PH, McWeeney S. Mapping cellular transcriptosomes in autopsied Alzheimer’s disease subjects and relevant animal models. Neurobiol Aging. 2006;27, 1060-77. DOI: 10.1016/j.neurobiolaging.2005.04.014
  2. Manczak M, Anekonda TS, Henson E, Park BS, Quinn J, Reddy PH. Mitochondria are a direct site of A beta accumulation in Alzheimer’s disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet. 2006;15, 1437-49. DOI: 10.1093/hmg/ddl066.
  3. Reddy PH. Mitochondrial oxidative damage in aging and Alzheimer’s disease: implications for mitochondrially targeted antioxidant therapeutics. J Biomed Biotechnol. 2006; 2006, 31372. DOI: 10.1155/JBB/2006/31372
  4. Reddy PH. Amyloid precursor protein-mediated free radicals and oxidative damage: implications for the development and progression of Alzheimer’s disease. J Neurochem. 2006;96, 1-13. DOI: 10.1111/j.1471-4159.2005.03530.x

 

2005

  1. Anekonda TS, Reddy PH. Neuronal protection by sirtuins in Alzheimer’s disease. J Neurochem. 2006;96, 305-13. DOI: 10.1111/j.1471-4159.2005.03492.x
  2. Anekonda TS, Reddy PH. Can herbs provide a new generation of drugs for treating Alzheimer’s disease? Brain Res Brain Res Rev. 2005;50, 361-76. DOI: 10.1016/j.brainresrev.2005.09.001
  3. Reddy PH, Beal MF. Are mitochondria critical in the pathogenesis of Alzheimer’s disease? Brain Res Brain Res Rev. 2005;49, 618-32. DOI: 10.1016/j.brainresrev.2005.03.004
  4. Reddy PH, Mani G, Park BS, Jacques J, Murdoch G, Whetsell W Jr, Kaye J, Manczak M. Differential loss of synaptic proteins in Alzheimer’s disease: implications for synaptic dysfunction. J Alzheimers Dis. 2005; 7, 103-17; discussion 173-80. DOI: 10.3233/JAD-2005-7203
  5. Manczak M, Jung Y, Park BS, Partovi D, Reddy PH. Time-course of mitochondrial gene expressions in mice brains: implications for mitochondrial dysfunction, oxidative damage, and cytochrome c in aging. J Neurochem. 2005;92, 494-504. DOI: 10.1111/j.1471-4159.2004.02884.x
  6. Sayer JA, Manczak M, Akileswaran L, Reddy PH, Coghlan VM. Interaction of the nuclear matrix protein NAKAP with HypA and huntingtin: implications for nuclear toxicity in Huntington’s disease pathogenesis. Neuromolecular Med. 2005; 7, 297-310.

DOI: 10.1385/NMM: 7:4:297

 

2004

  1. Reddy PH, McWeeney S, Park BS, Manczak M, Gutala RV, Partovi D, Jung Y, Yau V, Searles R, Mori M, Quinn J. Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer’s disease. Hum Mol Genet. 2004;13, 1225-40. DOI: 10.1093/hmg/ddh140.
  2. Gutala RV, Reddy PH. The use of real-time PCR analysis in a gene expression study of Alzheimer’s disease post-mortem brains. J Neurosci Methods. 2004; 132, 101-7. DOI: 10.1016/j.jneumeth.2003.09.005
  3. Manczak M, Park BS, Jung Y, Reddy PH. Differential expression of oxidative phosphorylation genes in patients with Alzheimer’s disease: implications for early mitochondrial dysfunction and oxidative damage. Neuromolecular Med. 2004; 5, 147-62. DOI: 10.1385/NMM: 5:2:147

2003

  1. Senatorov VV, Charles V, Reddy PH, Tagle DA, Chuang DM. Overexpression and nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase in a transgenic mouse model of Huntington’s disease. Mol Cell Neurosci. 2003; 22, 285-97. org/10.1016/S1044-7431 (02)00013-1

2001

  1. Laforet GA, Sapp E, Chase K, McIntyre C, Boyce FM, Campbell M, Cadigan BA, Warzecki L, Tagle DA, Reddy PH, Cepeda C, Calvert CR, Jokel ES, Klapstein GJ, Ariano MA, Levine MS, DiFiglia M, Aronin N. Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington’s disease. J Neurosci. 2001; 21, 9112-23. org/10.1523/JNEUROSCI.21-23-09112.2001
  2. Sun Y, Savanenin A, Reddy PH, Liu YF. Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95. J Biol Chem. 2001; 276, 24713-8. DOI: 10.1074/jbc.M103501200.
  3. Guidetti P, Charles V, Chen EY, Reddy PH, Kordower JH, Whetsell WO Jr, Schwarcz R, Tagle DA. Early degenerative changes in transgenic mice expressing mutant huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production. Exp Neurol. 2001; 169, 340-50. DOI: 10.1006/exnr.2000.7626.

2000

  1. Charles V, Mezey E, Reddy PH, Dehejia A, Young TA, Polymeropoulos MH, Brownstein MJ, Tagle DA. Alpha-synuclein immunoreactivity of huntingtin polyglutamine aggregates in striatum and cortex of Huntington’s disease patients and transgenic mouse models. Neurosci Lett. 2000; 289, 29-32. DOI: 10.1016/s0304-3940(00)01247-7
  2. Mastana SS, Reddy PH, Das MK, Reddy P, Das K. Molecular genetic diversity in 5 populations of Madhya Pradesh, India. Hum Biol. 2000; 72, 499-510. PMID: 10885195
  3. Guidetti P, Reddy PH, Tagle DA, Schwarcz R. Early kynurenergic impairment in Huntington’s disease and in a transgenic animal model. Neurosci Lett. 2000; 283, 233-5. DOI: 10.1016/s0304-3940(00)00956-3

1999

  1. Reddy PH, Charles V, Williams M, Miller G, Whetsell WO Jr, Tagle DA. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington’s disease. Philos Trans R Soc Lond B Biol Sci. 1999;354(1386):1035-45. DOI: 10.1098/rstb.1999.0456
  2. Reddy PH, Williams M, Tagle DA. Recent advances in understanding the pathogenesis of Huntington’s disease. Trends Neurosci. 1999; 22, 248-55. DOI: 10.1016/s0166-2236(99)01415-0
  3. Kim M, Lee HS, LaForet G, McIntyre C, Martin EJ, Chang P, Kim TW, Williams M, Reddy PH, Tagle D, Boyce FM, Won L, Heller A, Aronin N, DiFiglia M. Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition. J Neurosci. 1999; 19, 964-73. org/10.1523/JNEUROSCI.19-03-00964.1999.

 

1998

  1. Reddy PH, Williams M, Charles V, Garrett L, Pike-Buchanan L, Whetsell WO Jr, Miller G, Tagle DA. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat Genet. 1998; 20, 198-202. DOI: 10.1038/2510
  2. Mastana SS, Calderon R, Pena J, Reddy PH, Papiha SS. Anthropology of the apoplipoprotein E (apo E) gene: low frequency of apo E4 allele in Basques and in tribal (Baiga) populations of India. Ann Hum Biol. 1998; 25(2):137-43. DOI: 10.1080/03014469800005512

1999

  1. Reddy PH, Stockburger E, Gillevet P, Tagle DA. Mapping and characterization of novel (CAG)n repeat cDNAs from adult human brain derived by the oligo capture method. Genomics. 1997; 46(2):174-82. DOI: 10.1006/geno.1997.5044
  2. Reddy PH, Modell B. The Baigas of Madhya Pradesh: a demographic study. J Biosoc Sci. 1997; 29(1):19-31. DOI: 10.1017/s0021932097000199

 

1996

  1. Reddy PH, Modell B. Reproductive behaviour and natural selection for the sickle gene in the Baiga tribe of central India: the role of social parenting. Ann Hum Genet. 1996;60(3):231-6. DOI: 10.1111/j.1469-1809.1996.tb00426.x

1995

  1. Kaeda JS, Chhotray GP, Ranjit MR, Bautista JM, Reddy PH, Stevens D, Naidu JM, Britt RP, Vulliamy TJ, Luzzatto L, et al. A new glucose-6-phosphate dehydrogenase variant, G6PD Orissa (44 Ala–>Gly), is the major polymorphic variant in tribal populations in India. Am J Hum Genet. 1995; 57(6):1335-41. PMCID: PMC1801405
  2. Reddy PH, Tedder RS. Hepatitis virus markers in the Baiga tribal population of Madhya Pradesh, India. Trans R Soc Trop Med Hyg. 1995; 89(6):620.
  3. Reddy PH, Petrou M, Reddy PA, Tiwary RS, Modell B. Hereditary anaemias and iron deficiency in a tribal population (the Baiga) of central India. Eur J Haematol. 1995; 55(2):103-9. DOI: 10.1111/j.1600-0609.1995.tb01818.x
  4. Reddy PH, Modell B.Consanguinity and reproductive behaviour in a tribal population ‘the Baiga’ in Madhya Pradesh, India. Ann Hum Biol. 1995; 22(3):235-46. DOI: 10.1080/03014469500003892
  5. Reddy PH, Mastana SS. Genetic variation of serum proteins (GC, TF and PI subtypes) in the Baigas of Madhya Pradesh, India. Anthropol Anz. 1995; 53(1):53-6. PMID: 7755374
  6. Reddy PH and Modell B (1992). Hereditary anaemias and tribal populations in India. Galton Institute Newsletter 4, 5.

 

Lead Author Publications

 

  1. Reddy PH. Lifestyle and Risk Factors of Dementia in Rural West Texas. JAlzheimers Dis. 2019;72(s1):S1-S10. doi: 10.3233/JAD-191280. PubMed PMID: 31884491.
  2. Reddy PH. Current status of stem cell research: An editorial. Biochim Biophys Acta Mol Basis Dis. 2019 Dec 17:165635. doi: 10.1016/j.bbadis.2019.165635. [Epub ahead of print] PubMed PMID: 31862303.
  3. Reddy PH, Oliver DM. Amyloid Beta and Phosphorylated Tau-Induced Defective Autophagy and Mitophagy in Alzheimer’s Disease. Cells. 2019;8(5). pii: E488.

doi: 10.3390/cells8050488.

  1. Reddy PH, Swerdlow RH, Culberson J, Kang D, Mitchell TL, Smith Q, Suneja S, Ory MG, Kumar S, Vijayan M, Morsy A, Arandia G, Lawrence JJ, George E, Oliver D, Pradeepkiran JA, Yin X, Reddy AP, Manczak M, Cengiz P, Karamyan VT, Kandimalla R, Kuruva CS, Willms J, Ramasubramanian B, Sawant N, Burugu D, Boles AN, Lopez V, Carrasco R, Aguirre C, Thompson S, Blackmon J, Ament C, Wang R, Stephens ER, Hoang B, Bass K, Trippier PC, Hornback C, Kottapalli P, Kottapalli KR; Center Biotechnology and Genetics Core Facility, Oddo S. Current Status of Healthy Aging and Dementia Research: A Symposium Summary. J Alzheimers Dis. 2019.

doi: 10.3233/JAD-190252.

  1. Reddy PH, Yin X, Manczak M, Kumar S, Pradeepkiran JA, Vijayan M, Reddy AP. Mutant APP and amyloid beta-induced defective autophagy, mitophagy, mitochondrial structural and functional changes and synaptic damage in hippocampal neurons from Alzheimer’s disease. Hum Mol Genet. 2018; 27(14):2502-2516.

doi: 10.1093/hmg/ddy335.

  1. Reddy PH, Manczak M, Yin X, Reddy AP. Synergistic Protective Effects of Mitochondrial division inhibitor and mitochondria-targeted antioxidant peptide SS31 in Alzheimer’s Disease. J Alzheimers Dis, 2018; 62, 1549-1565. doi: 10.3233/JAD-170988.
  2. Reddy PH. Can Diabetes Be Controlled by Lifestyle Activities? Curr Res Diabetes Obes J. 1(4). pii: 555568. PubMed PMID: 29399663; PubMed Central PMCID: PMC5792082.
  3. Reddy PH, Manczak M, Yin X, Grady MC, Mitchell A, Tonk S, Kuruva CS, Bhatti JS, Kandimalla R, Vijayan M, Kumar S, Wang R, Pradeepkiran JA, Ogunmokun G, Thamarai K, Quesada K,Boles A, Reddy AP. Protective Effects of Indian Spice Curcumin Against Amyloid-β in Alzheimer’s Disease. J Alzheimers Dis. 2018; 61, 843-866. doi: 10.3233/JAD-170512.
  4. Reddy PH, Manczak M, Kandimalla R. Mitochondria-targeted small molecule SS31: a potential candidate for the treatment of Alzheimer’s disease. Hum Mol Genet. 2017;26(8):1597. doi: 10.1093/hmg/ddx129.
  5. Reddy PH. A Critical Assessment of Research on Neurotransmitters in Alzheimer’s Disease. J Alzheimers Dis. 2017; 57, 969-974. doi: 10.3233/JAD-170256.
  6. Reddy PH, Manczak M, Yin X. Mitochondria-Division Inhibitor 1 Protects Against Amyloid-β induced Mitochondrial Fragmentation and Synaptic Damage in Alzheimer’s  J Alzheimers Dis. 2017; 58, 147-162. doi: 10.3233/JAD-170051.
  7. Reddy PH, Williams J, Smith F, Bhatti JS, Kumar S, Vijayan M, Kandimalla R, Kuruva CS, Wang R, Manczak M, Yin X, Reddy AP. MicroRNAs, Aging, Cellular Senescence, and Alzheimer’s Disease. Prog Mol Biol Transl Sci. 2017; 146, 127-171.

doi: 10.1016/bs.pmbts.2016.12.009.

  1. Reddy PH. Editorial of the article. Biochim Biophys Acta. 2017; 1863, 1023-1025. DOI: 10.1016/j.bbadis.2017.02.010.
  2. Reddy PH, Manczak M, Kandimalla R. Mitochondria-targeted small molecule SS31: a potential candidate for the treatment of Alzheimer’s disease. Hum Mol Genet. 2017; 26, 1483-1496. doi: 10.1093/hmg/ddx052.
  3. Reddy PH, Tonk S, Kumar S, Vijayan M, Kandimalla R, Kuruva CS, Reddy AP. A critical evaluation of neuroprotective and neurodegenerative MicroRNAs in Alzheimer’s disease. Biochem Biophys Res Commun. 2017; 483, 1156-1165.

doi: 10.1016/j.bbrc.2016.08.067.

  1. Reddy PH, Manczak M, Yin X, Grady MC, Mitchell A, Kandimalla R, Kuruva CS. Protective effects of a natural product, curcumin, against amyloid β induced mitochondrial and synaptic toxicities in Alzheimer’s disease. J Investig Med. 2016; 64(8):1220-1234. DOI: 10.1136/jim-2016-000240.
  2. Reddy PH, Blackmon J, Molinar-Lopez V, Ament C, Manczak M, Kandimalla R, Yin X, Pandey AK, Kuruva CS, Wang R, Fry DR, Osborn C, Stonum K, Quesada K, Gonzales R and Boles Garrison Institute on Aging – A New Hope for Elderly Individuals and Patients with Alzheimer’s Disease. J Alzheimers Dis 2015; 48, 547-555.

doi: 10.3233/JAD-150490.

  1. Reddy PH. Editorial of a special issue – ‘Misfolded Proteins, Mitochondrial Dysfunction and Neurodegenerative Diseases, Biochim Biophys Acta, 2014; 1842, 1167.

doi: 10.1038/srep06861.

  1. Reddy PH. Increased mitochondrial fission and neuronal dysfunction in Huntington’s disease: implications for molecular inhibitors of excessive mitochondrial fission. Drug Discov Today. 2014; 19, 951-5.doi: 10.1016/j.drudis.2014.03.020.
  2. Reddy PH. Inhibitors of mitochondrial fission as a therapeutic strategy for diseases with oxidative stress and mitochondrial dysfunction. J Alzheimers Dis. 2014;40, 245-56.

doi: 10.3233/JAD-132060.

  1. Reddy PH. Amyloid beta-induced glycogen synthase kinase 3β phosphorylated VDAC1 in Alzheimer’s disease: implications for synaptic dysfunction and neuronal damage. Biochim Biophys Acta. 2013; 1832, 1913-21. doi: 10.1016/j.bbadis.2013.06.012.
  2. Reddy PH. Is the mitochondrial outermembrane protein VDAC1 therapeutic target for Alzheimer’s disease? Biochim Biophys Acta. 2013; 1832, 67-75.

doi: 10.1016/j.bbadis.2012.09.003.

  1. Reddy PH, Tripathi R, Troung Q, Tirumala K, Reddy TP, Anekonda V, Shirendeb UP, Calkins MJ, Reddy AP, Mao P, Manczak M. Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer’s disease: implications to mitochondria-targeted antioxidant therapeutics. Biochim Biophys Acta. 2012; 1822, 639-49. doi: 10.1016/j.bbadis.2011.10.011.
  2. Reddy PH. Editorial of a special issue. Current status of therapeutics and preventive measures for patients with thalassaemia and sickle cell disease. Cardiovasc Hematol Agents Med Chem. 2012; 10, 2. DOI : 10.2174/187152512799201154
  3. Reddy PH, Shirendeb UP. Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington’s disease. Biochim Biophys Acta. 2012; 1822, 101-10.

doi: 10.1016/j.bbadis.2011.10.016.

  1. Reddy PH. Abnormal tau, mitochondrial dysfunction, impaired axonal transport of mitochondria, and synaptic deprivation in Alzheimer’s disease. Brain Res. 2011;1415, 136-48. doi: 10.1016/j.brainres.2011.07.052.
  2. Reddy PH, Reddy TP, Manczak M, Calkins MJ, Shirendeb U, Mao P. Dynamin-related protein 1 and mitochondrial fragmentation in neurodegenerative diseases. Brain Res Rev. 2011 Jun 24;67(1-2):103-18. doi: 10.1016/j.brainresrev.2010.11.004.
  3. Reddy PH, Reddy TP. Mitochondria as a therapeutic target for aging and neurodegenerative diseases. Curr Alzheimer Res. 2011; 8, 393-409. DOI: 10.2174/156720511795745401.
  4. Reddy PH, Manczak M, Mao P, Calkins MJ, Reddy AP, Shirendeb U. Amyloid-beta and mitochondria in aging and Alzheimer’s disease: implications for synaptic damage and cognitive decline. J Alzheimers Dis. 2010;20 Suppl 2:S499-512.

doi: 10.3233/JAD-2010-100504.

  1. Reddy PH, Manczak M, Zhao W, Nakamura K, Bebbington C, Yarranton G, Mao P. Granulocyte-macrophage colony-stimulating factor antibody suppresses microglial activity: implications for anti-inflammatory effects in Alzheimer’s disease and multiple sclerosis. J Neurochem. 2009; 111, 1514-28. doi: 10.1111/j.1471-4159.2009.06432.x.
  2. Reddy PH. Role of mitochondria in neurodegenerative diseases: mitochondria as a therapeutic target in Alzheimer’s disease. CNS Spectr. 2009; 14(8 Suppl 7):8-13; discussion 16-8. DOI: 10.1017/s1092852900024901.
  3. Reddy PH, Mao P, Manczak M. Mitochondrial structural and functional dynamics in Huntington’s disease. Brain Res Rev. 2009; 61, 33-48. doi: 10.1016/j.brainresrev.2009.04.001.
  4. Reddy PH, Beal MF. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer’s disease. Trends Mol Med. 2008; 14, 45-53. doi: 10.1016/j.molmed.2007.
  5. Reddy PH. Mitochondrial medicine for aging and neurodegenerative diseases. Neuromolecular Med. 2008;10(4):291-315. doi: 10.1007/s12017-008-8044-z.
  6. Reddy PH. Mitochondrial dysfunction in aging and Alzheimer’s disease: strategies to protect neurons. Antioxid Redox Signal. 2007; 9(10):1647-58.

DOI: 10.1089/ars.2007.1754.

  1. Reddy PH, McWeeney S. Mapping cellular transcriptosomes in autopsied Alzheimer’s disease subjects and relevant animal models. Neurobiol Aging. 2006;27, 1060-77. DOI: 10.1016/j.neurobiolaging.2005.04.014
  2. Reddy PH. Mitochondrial oxidative damage in aging and Alzheimer’s disease: implications for mitochondrially targeted antioxidant therapeutics. J Biomed Biotechnol. 2006; 2006, 31372. DOI: 10.1155/JBB/2006/31372
  3. Reddy PH. Amyloid precursor protein-mediated free radicals and oxidative damage: implications for the development and progression of Alzheimer’s disease. J Neurochem. 2006;96, 1-13. DOI: 10.1111/j.1471-4159.2005.03530.x
  4. Reddy PH, Beal MF. Are mitochondria critical in the pathogenesis of Alzheimer’s disease? Brain Res Brain Res Rev. 2005;49, 618-32. DOI: 10.1016/j.brainresrev.2005.03.004
  5. Reddy PH, Mani G, Park BS, Jacques J, Murdoch G, Whetsell W Jr, Kaye J, Manczak M. Differential loss of synaptic proteins in Alzheimer’s disease: implications for synaptic dysfunction. J Alzheimers Dis. 2005; 7, 103-17; discussion 173-80. DOI: 10.3233/JAD-2005-7203
  6. Reddy PH, McWeeney S, Park BS, Manczak M, Gutala RV, Partovi D, Jung Y, Yau V, Searles R, Mori M, Quinn J. Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer’s disease. Hum Mol Genet. 2004;13, 1225-40. DOI: 10.1093/hmg/ddh140.
  7. Reddy PH, Charles V, Williams M, Miller G, Whetsell WO Jr, Tagle DA. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington’s disease. Philos Trans R Soc Lond B Biol Sci. 1999;354(1386):1035-45. DOI: 10.1098/rstb.1999.0456
  8. Reddy PH, Williams M, Tagle DA. Recent advances in understanding the pathogenesis of Huntington’s disease. Trends Neurosci. 1999; 22, 248-55. DOI: 10.1016/s0166-2236(99)01415-0
  9. Reddy PH, Stockburger E, Gillevet P, Tagle DA. Mapping and characterization of novel (CAG)n repeat cDNAs from adult human brain derived by the oligo capture method. Genomics. 1997; 46(2):174-82. DOI: 10.1006/geno.1997.5044

Reddy PH, Modell B. The Baigas of Madhya Pradesh: a demographic study. J Biosoc Sci. 1997; 29(1):19-31. DOI: 10.1017/s0021932097000199

  1. Reddy PH, Modell B. Reproductive behaviour and natural selection for the sickle gene in the Baiga tribe of central India: the role of social parenting. Ann Hum Genet. 1996;60(3):231-6. DOI: 10.1111/j.1469-1809.1996.tb00426.x
  2. Reddy PH. The health of the aged in India. PMID: 10172870
  3. Reddy PH, Tedder RS. Hepatitis virus markers in the Baiga tribal population of Madhya Pradesh, India. Trans R Soc Trop Med Hyg. 1995; 89(6):620.
  4. Reddy PH, Petrou M, Reddy PA, Tiwary RS, Modell B. Hereditary anaemias and iron deficiency in a tribal population (the Baiga) of central India. Eur J Haematol. 1995; 55(2):103-9. DOI: 10.1111/j.1600-0609.1995.tb01818.x
  5. Reddy PH, Modell B.Consanguinity and reproductive behaviour in a tribal population ‘the Baiga’ in Madhya Pradesh, India. Ann Hum Biol. 1995; 22(3):235-46. DOI: 10.1080/03014469500003892
  6. Reddy PH, Mastana SS. Genetic variation of serum proteins (GC, TF and PI subtypes) in the Baigas of Madhya Pradesh, India. Anthropol Anz. 1995; 53(1):53-6. PMID: 7755374

 

 

 

Single Author Publications

 

  1. Reddy PH. Lifestyle and Risk Factors of Dementia in Rural West Texas. JAlzheimers Dis. 2019;72(s1):S1-S10. doi: 10.3233/JAD-191280. PubMed PMID: 31884491.
  2. Reddy PH. Current status of stem cell research: An editorial. Biochim Biophys Acta Mol Basis Dis. 2019 Dec 17:165635. doi: 10.1016/j.bbadis.2019.165635. [Epub ahead of print] PubMed PMID: 31862303.
  3. Reddy PH. Can Diabetes Be Controlled by Lifestyle Activities? Curr Res Diabetes Obes J. 1(4). pii: 555568. PubMed PMID: 29399663; PubMed Central PMCID: PMC5792082.
  4. Reddy PH. A Critical Assessment of Research on Neurotransmitters in Alzheimer’s Disease. J Alzheimers Dis. 2017; 57, 969-974. doi: 10.3233/JAD-170256.
  5. Reddy PH. Editorial of the article. Biochim Biophys Acta. 2017; 1863, 1023-1025. DOI: 10.1016/j.bbadis.2017.02.010.
  6. Reddy PH. Increased mitochondrial fission and neuronal dysfunction in Huntington’s disease: implications for molecular inhibitors of excessive mitochondrial fission. Drug Discov Today. 2014; 19, 951-5. doi: 10.1016/j.drudis.2014.03.020.
  7. Reddy PH. Inhibitors of mitochondrial fission as a therapeutic strategy for diseases with oxidative stress and mitochondrial dysfunction. J Alzheimers Dis. 2014;40, 245-56. doi: 10.3233/JAD-132060.
  8. Reddy PH. Amyloid beta-induced glycogen synthase kinase 3β phosphorylated VDAC1 in Alzheimer’s disease: implications for synaptic dysfunction and neuronal damage. Biochim Biophys Acta. 2013; 1832, 1913-21. doi: 10.1016/j.bbadis.2013.06.012.
  9. Reddy PH. Is the mitochondrial outermembrane protein VDAC1 therapeutic target for Alzheimer’s disease? Biochim Biophys Acta. 2013; 1832, 67-75. doi: 10.1016/j.bbadis.2012.09.003.
  10. Reddy PH. Editorial of a special issue. Current status of therapeutics and preventive measures for patients with thalassaemia and sickle cell disease. Cardiovasc Hematol Agents Med Chem. 2012; 10, 2. DOI : 10.2174/187152512799201154
  11. Reddy PH. Abnormal tau, mitochondrial dysfunction, impaired axonal transport of mitochondria, and synaptic deprivation in Alzheimer’s disease. Brain Res. 2011;1415, 136-48. doi: 10.1016/j.brainres.2011.07.052.
  12. Reddy PH. Role of mitochondria in neurodegenerative diseases: mitochondria as a therapeutic target in Alzheimer’s disease. CNS Spectr. 2009; 14(8 Suppl 7):8-13; discussion 16-8. DOI: 10.1017/s1092852900024901.
  13. Reddy PH. Mitochondrial medicine for aging and neurodegenerative diseases. Neuromolecular Med. 2008;10(4):291-315. doi: 10.1007/s12017-008-8044-z.
  14. Reddy PH. Mitochondrial dysfunction in aging and Alzheimer’s disease: strategies to protect neurons. Antioxid Redox Signal. 2007; 9(10):1647-58. DOI: 10.1089/ars.2007.1754.
  15. Reddy PH. Mitochondrial oxidative damage in aging and Alzheimer’s disease: implications for mitochondrially targeted antioxidant therapeutics. J Biomed Biotechnol. 2006; 2006, 31372. DOI: 10.1155/JBB/2006/31372
  16. Reddy PH. Amyloid precursor protein-mediated free radicals and oxidative damage: implications for the development and progression of Alzheimer’s disease. J Neurochem. 2006;96, 1-13. DOI: 10.1111/j.1471-4159.2005.03530.x
Book Chapters

Reddy PH (2010) Neurogenetics of Aging (Chapter 3) in Clinical Neurology of Aging Edited by Martin Albert Janice Knoefel, Oxford University Publications.

Reddy PH, Charles V, Whetsell Jr WO and Tagle DA (2001). Behavioural changes and selective neuronal loss in full-length transgenic mouse models for Huntington Disease. Edited by PS Harper and M Perutz. In, polyglutamine repeats and neurodegenerative diseases.  Oxford University Publications, Pages 41-64.

Reddy PH and Tagle DA (1999). The Biology of Trinucleotide repeat diseases. Edited by M. Mattson. In,            Genetic aberrancies and neurodegenerative diseases. (Jai Publications), Advances in Cell Aging and Gerontology, Volume 3, Pages 33-79.

Reddy PH. Preface. Prog Mol Biol Transl Sci. 2017;146:xvii-xx. doi: 10.1016/S1877-1173(17)30028-5.                PubMed PMID: 28253993. Molecular Biology of Aging.Vijayan M, Kumar S, Bhatti JS, Reddy PH. Molecular Links and Biomarkers of Stroke, Vascular Dementia, and Alzheimer’s Disease. Prog Mol Biol Transl Sci. 2017;146:95-126. Molecular Biology of Aging. Kumar S, Vijayan M, Bhatti JS, Reddy PH. MicroRNAs as Peripheral Biomarkers in Aging and Age-               Related Diseases. Prog Mol Biol Transl Sci. 2017;146:47-94. Molecular Biology of Aging.Reddy AP, Reddy PH. Mitochondria-Targeted Molecules as Potential Drugs to Treat Patients With Alzheimer’s Disease. Prog Mol Biol Transl Sci. 2017;146:173-201. Molecular Biology of Aging.Bhatti JS, Kumar S, Vijayan M, Bhatti GK, Reddy PH. Therapeutic Strategies for Mitochondrial                Dysfunction and Oxidative Stress in Age-Related Metabolic Disorders. Prog Mol Biol Transl Sci.                2017;146:13-46. Molecular Biology of Aging.Reddy PH, Williams J, Smith F, Bhatti JS, Kumar S, Vijayan M, Kandimalla R, Kuruva CS, Wang R, Manczak M, Yin X, Reddy AP. MicroRNAs, Aging, Cellular Senescence, and Alzheimer’s Disease. Prog Mol Biol Transl Sci. 2017;146:127-171. Molecular Biology of Aging.

Reddy PH, Manczak M, Yin X, Grady MC, Mitchell A, Tonk S, Kuruva CS, Bhatti JS, Kandimalla R,       Vijayan M, Kumar S, Wang R, Pradeepkiran JA, Ogunmokun G, Boles A and Reddy AP. Natural      Products and Health Benefits to Human Diseases: Focus on Curcumin and Alzheimer’s Disease.          In press, 2019, Springer Nature, Nature Publishing Group.

 

Book Reviews

Reddy PH (2004). Huntington’s Disease – Edited by Gillian Bates, Peter S. Harper and Lesley Jones, Oxford Publications. Book Review.  American Journal of Human Genetics. 74,781-782.

 

Invited Commentaries in Alzheimer Research Forum

  1. Wrote an invited commentary on Science article by Schriner SE, Linford NJ, Martin GM, Treuting P Ogburn CE, Emond M, Coskun PE, Ladiges W, Wolf N, Van Remmen H, Wallace DC,    Rabinovitch PS Extension of Murine Lifespan by Overexpression of Catalase Targeted to  Mitochondria. Science. 2005: 308, 1909-1911.
  2. Wrote an invited commentary on JBC article by Falkevall A, Alikhani N, Bhushan S, Pavlov PF, Busch K, Johnson KA, Eneqvist T, Tjernberg L, Ankarcrona M, Glaser E. Degradation of the amyloid beta-protein by the novel mitochondrial peptidasome, PreP. J Biol Chem. 2006: 281, 29096     29104.
  3. Wrote an invited commentary on Nature Medicine article by Du H, Guo L, Fang F, Chen D, Sosunov AA, McKhann GM, Yan Y, Wang C, Zhang H, Molkentin JD, Gunn-Moore FJ, Vonsattel JP, Arancio O, Chen JX, Yan SD. Cyclophilin D deficiency attenuated mitochondrial and neuronal           perturbation and ameliorates learning and memory in Alzheimer’s disease. Nature Medicine     2008: 14, 1097-1105.
  4. Wrote an invited commentary on PNAS article by Massaad CA, Washington TM, Pautler RG, Klann E. Overexpression of SOD-2 reduces hippocampal superoxide and prevents memory deficits in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A. 2009 Aug 11;106(32):13576-81 .
  5. Wrote an invited commentary on PLOSONE article by Sanz-Blasco S, Valero RA, Rodríguez-Crespo I, Villalobos C, Núñez L. Mitochondrial Ca2+ overload underlies Abeta oligomers neurotoxicity providing an unexpected mechanism of neuroprotection by NSAIDs. PLoS ONE.     2008;3(7):e2718.
  6. Wrote an invited commentary on Winton MJ, Lee EB, Sun E, Wong MM, Leight S, Zhang B, Trojanowski JQ, Lee VM. Intraneuronal APP, not free Aß peptides in 3xTg-AD mice: implications for tau versus Aß-mediated Alzheimer neurodegeneration. J Neurosci. 2011 May 25;31(21):7691         7699.

 

Invited Seminars, Talks and Plenary Lectures at National and International Conferences/Meetings By P. Hemachandra Reddy – In Reverse Chronological Order

 

2019

1.Invited plenary presentation ‘Early Cellular Changes in Alzheimer’s Disease’  at the International

Conference on Neurological Diseases and Therapeutics,  Gandhinagar, India, organized by National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad.

  1. Invited talk ‘Protective Role of Reduced Drp1 in Alzheimer’s Disease by Dr. Kim Tieu, Florida International University, March 28, 2019.
  2. Invited talk ‘MicroRNAs as Early Detectable Biomarkers for Alzheimer’s Disease and Ischemic Stroke’ by Dr. H Lee, University of Texas, San Antonio, Feb 4, 2019.

2018

  1. Invited talk ‘Reduced Dynamin-related Protein 1 and Neuroprotection in Alzheimer’s Disease’ by Dr David Kang, University South Florida, Tampa, November 2, 2018.
  2. Invited talk ‘What We Learned About Alzheimer’s Synapses and Mitochondria’ by Dr. Lisa Stanek, Neuroscience Division, Sanofi, Boston, MA September 5, 2018
  3. Invited Plenary Lecture ‘Abnormal Mitochondrial Dynamics and Defective Synapses: Protective Role

of Reduced Dynamin-Related Protein 1 in Alzheimer’s Disease’ at Second International Conference on Neurology and Brain Diseases, Rome Italy, June 3-6, 2018.

7. Invited Presentation ‘Abnormal Mitochondrial Dynamics and Defective Synapses’ invited by Dr. Pearl Merritt, Regional Dean of School of Pharmacy, TTUHSC at 6th Annual Abilene Alzheimer’s          Symposium, May 4, 2018.
  1. Invited Presentation ‘Can Lifestyle Activities Delay and/or Prevent Alzheimer’s Dementia in Elderly Individuals’ by Dr. Heather Caldwell at 6th Annual Neuroscience Symposium, Kent State University, Ohio, April 25-26, 2018

2017

  1. Invited talk ‘Synaptic Mitochondrial Damage in Alzheimer’s Disease’ by Dr. Krishna Bhatt, Professor of

Cell Biology and Neuroscience Department, University of Medical Branch, Galveston, TX, December 6, 2017.

  1. Invited talk ‘Defective Synapses and Mitochondria in Alzheimer’s Disease’ by Dr. Alvin Terry, Associate Vice President for Basic Science Research, Regents Professor and Chair Department of Pharmacology and Toxicology Medical College of Georgia at Augusta University, September  25, 2017.
  2. Invited presentation ‘Mitochondrial Fragmentation and Neurodegeneration in Huntington’s Disease at Graduate Faculty Retreat, Graduate School of Biomedical Sciences, Texas Tech University Health Sciences Center, Lubbock, TX, September 22, 2017.
  3. Invited talk ‘Mitochondrial Fragmentation and Synaptic Damage in Alzheimer’s disease’ by Dr. Asgar Zaheer, Director for Center for Translational Neuroscience, University of Missouri – School of Medicine, Columbia, MO August 14, 2017.
  4. Invited presentation ‘Recent Research at Garrison Institute on Aging – Focus on Women’s Health’ by Ms. Laura Logan, Director Communications, Leadership Women, May 7-9, 2017.
  5. Invited talk ‘Mitochondria-targeted Molecules and Alzheimer’s Disease by Qian Cai, Department of Cell Biology and Neuroscience, Rutgers, The State University of New Jersey, Piscataway, NJ, March 17, 2017.
  6. Invited talk entitled ‘Synapses and Mitochondria in Alzheimer’s Disease by Dr. Anil Kumar, Chair of Pharmacology and Toxicology, UMKC-School of Pharmacy, Kansas City, February 9, 2017.
  7. Invited presentation entitled ‘Recent Advances in Alzheimer’s Disease Pathogenesis: Molecular Basis and Therapeutics, for Korean students of Hallym University, who visited TTUHSC,      February 3, 2017

2016 

  1. Invited presentation entitled ‘Amyloid beta, Dynamin-related Protein 1 and Synaptic Damage in Alzheimer’s Disease’ by Dr. Susan Bergeson, Director of Graduate School of Biomedical Sciences Biotechnology, TTUHSC, November 18, 2016.
  2. Invited talk entitled ‘Are Mitochondria Protective Against Amyloid beta-induced Synaptic Damage in Alzheimer’s Disease’ by Nick Brustovetsky, Ph.D., Professor and Showalter Scholar, Department of Pharmacology and Toxicology, Stark Research Institute, Indiana University School of  Medicine, November 2-3, 2016.
  3. Invited seminar entitled ‘Mitochondria-Targeted Molecules As Potential Therapeutic Targets’ at the Alzheimer’s Association International Conference, July 24-28, 2016, Toronto, Canada.
  4. Invited seminar entitled ‘Oxidative Stress, Mitochondrial Dysfunction and Defective Synapses in Alzheimer’s Disease, on January 22, 2016 at NSM Biological Sciences 2016 Spring Seminar Series, University of Texas, Dallas.
  5. Invited Plenary presentation entitled ‘Is Mitochondrial Impairment A Key Factor For Aging and Alzheimer’s Disease? on January 11, 2016 at Sri Venkateswara University, Tirupathi, India.

2015

  1. Invited seminar entitled ‘Advances in Alzheimer’ Neurology & Epilepsy Grand Round Series on Wednesday, December 2nd, 2015 at the Overton Hotel & Conference Center in Lubbock, TX.
  2. Invited Healthy Aging Seminar entitled ‘Can Healthy Diets, regular exercise and better lifestyle can delay progression of dementia in elderly individuals? Garrison Institute on Aging Healthy Aging   Lecture Series, November 18, 2015.
  3. Plenary Lecture entitled ‘Mitochondrial division inhibitor 1 protects against mutant huntingtin-induced abnormal mitochondrial dynamics and neuronal damage in Huntington’s disease’ at 33rd Indian   Academy of Neurosciences, Chandigarh, India October 30-November 2,            2015.
  4. Invited talk entitled ‘Is Impaired Mitochondria Dynamics A Key Factor For Aging and Alzheimer’s Disease?’ at International Brain Research Organization School, Chandigarh, India. October 26 30, 2015.
  5. Invited talk entitled ‘Stress, Dysfunction & Aging: Culprit Affecting Our Cells…. Garden & Arts Center at 44th St. and University Ave. Lubbock, September 22, 2015.
  6. Invited talk entitled ‘Defective Synapses and Mitochondrial Dysfunction’ at Faculty Retreat, TTUHSC, Lubbock, September 11, 2015.
  7. Invited Guest Lecture entitled ‘Molecular Mechanisms of Aging and Alzheimer’s disease’ for neuroscience course for speech and hearing science seniors, Department of Speech, Language, & Hearing Sciences, Texas Tech University Health Sciences Center,      September 13,            2015
  8. Invited talk entitled ‘Is Mitochondrial Dysfunction a Trigger for Alzheimer’s Disease Pathogenesis? Department of Cell Biology & Biochemistry, Texas Tech University Health Sciences Center, Lubbock, Texas, June 26, 2015.
  9. Invited talk entitled ‘Oxidative Stress and Mitochondrial Dysfunction in Aging and Alzheimer’s Disease, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas, April 29, 2015.
  10. Invited talk entitled ‘Mitochondria, Oxidative Stress and Neurodegenerative Diseases’, Neurology Department, Texas Tech University Health Sciences Center, Lubbock, Texas, April 27,           2015.
  11. Invited talk entitled ‘Inhibitors of Mitochondrial Fission as a Therapeutic Strategy for Diseases with Oxidative Stress and Mitochondrial Dysfunction’, Mitochondrial Targeting & Toxicity, Cambridge Health Tech Conference, March 2015.
  12. Invited talk entitled ‘Oxidative Stress and Mitochondrial Dysfunction in Aging, Alzheimer’s Disease and Obesity/Diabetes’ at Obesity Research Cluster and Nutritional Sciences, Texas Tech University, Lubbock – February 19, 2015.
  13. Invited talk entitled ‘Mitochondrial approaches to treat neurodegenerative diseases’ at 2015 Translational Research Seminars by Department of Internal Medicine, Texas Tech University Health Sciences Center – March 4, 2015.
  14. Invited Grand Round Lecture entitled ‘Mitochondrial Dysfunction in Neurodegenerative Diseases’ at Neurology Department, Texas Tech University Health Sciences Center, March 3, 2015.
  15. Invited talk entitled ‘Inhibitors of Mitochondrial Fission as a Therapeutic Strategy for Diseases with Oxidative Stress and Mitochondrial Dysfunction’ at symposium –Mitochondrial Targeting & Toxicity organized by Cambridge Health Tech Conference, March 19-21, 2015
  16. Garrison Institute on Aging Research, TTUHSC Seminar A New Direction of Research in Aging and Neurodegenerative Disease’ Part 3 – Focus on Huntington’s Disease presented on January 6, 2015

2014

  1. Garrison Institute on Aging, TTUHSC Research Seminar ‘A New Direction of Research in Aging and Neurodegenerative Disease’ Part 2 – Reduced Alzheimer’s Disease and Longevity in Alzheimer’s Disease presented on December 2, 2014
  2. Garrison Institute on Aging, TTUHSC Healthy Aging Lecture Series entitled ‘Alzheimer’s Disease: Cell Damage and Defective Synapses, Research and Preventive Measures presented on November 19, 2014
  3. Garrison Institute on Aging, TTUHSC Research Seminar ‘A New Direction of Research in Aging and Neurodegenerative Disease’ Part 1 – Introduction, presented on November 7, 2014
  4. Invited talk entitled ‘Mitochondrial Dysfunction in Alzheimer’s Disease’ at Texas Tech University Health Sciences Center, Lubbock, Texas on March 13, 2014.
  5. Invited talk entitled ‘Mitochondrial Dysfunction in Aging and Alzheimer’s Disease at the Department of Pharmacology & Neuroscience, University of North Texas, Fort Worth, Texas on Feb 25, 2014.
  6. Invited talk entitled ‘Mitochondrial Damage and Defective Synapses in Alzheimer’s Disease’ at the Department of Physiology and Biophysics, Case Western Reserve University, Cleveland, Ohio,  January 27, 2014.

2013

  1. Invited talk entitled ‘Mitochondria-Targeted Molecules and Neuroprotection in Alzheimer’s Disease’ at the Department of Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, December 4, 2013.
  2. Invited talk entitled ‘Defective Synapses and Oxidative Stress in Neurodegenerative Diseases’ at the 23rd Neuropharmacology Conference of The Synaptic Basis of Neurodegenerative Diseases, and      A satellite meeting to Society for Neuroscience to be held at San Diego 7-8 November 2013.
  3. Invited talk entitled ‘Mitochondria-Targeted Drugs To Treat Patients With Alzheimer’s Disease’ on June 5, at the Drug Discovery and Therapy World Congress of the John B. Hynes Veterans Memorial Convention Center, June 5, 2013, Boston.
    47. Invited talk entitled ‘Are Mitochondria Critical For Synaptic Activity and Neuronal Function in  Alzheimer’s Disease’? at the Wellesley College Summer Research Program on June 6, 2013, Wellesley.
  4. Invited talk ‘Drug Screening – Fusion/Fission Modulators’ at the Neuromuscular Disorders of Mitochondrial Fusion and Fission to be held European Neuromuscular Center, in NH Naarden Hotel, The Netherlands, April 26-28, 2013.
  5. Invited talk ‘Mitochondrial Dysfunction and Oxidative Stress in Alzheimer’s Disease’ at the Anesthesiology and Peri-operative Medicine Department of Oregon Health and Science University, February 6, 2013.

2012

  1. Invited talk entitled ‘Mitochondria-Targeted Catalase Reduces Abnormal APP Processing, Amyloid beta Production and BACE1 in a Mouse Models of Alzheimer’s Disease: Implications for Neuroprotection and Lifespan Extension’ at the 7th International Conference of the Coenzyme   Q10, held in Seville – Spain, November 8-11, 2012.
  2. Invited talk entitled ‘Amyloid Beta Induced Impaired Mitochondrial Dynamics and Synaptic Degeneration in Alzheimer’s Disease’ at the Barshop Institute of Aging, University of Texas Health Center, San Antonio, September 25-27, 2012.
  3. Invited talk entitled ‘Amyloid Beta and Mitochondria in Alzheimer’s Disease’ by at the Alzheimer’s Disease Center, Karolinska Institute, Stockholm, Sweden, September 11-16, 2012.

2011

  1. Invited talk entitled ‘Mitochondria as Drug Targets’ at a Symposium on Alzheimer`s Disease: New perspectives on therapeutic targets and pathways’ held in Frankfurt, Germany, August 25-27,      2011.

2010

  1. Invited faculty seminar entitled “Abnormal Mitochondrial Dynamics and Synaptic Damage in Alzheimer’s Disease: Implications Cognitive Decline” at the Medical and Molecular Genetics Department, Oregon Health and Science University, December 1, 2010.
  2. Invited faculty seminar entitled “Abnormal Mitochondrial Dynamics in Alzheimer’s Disease: Implications for Synaptic Damage and Cognitive Decline” at the Pharmacology Department, Temple University School of Medicine, Philadelphia, November 3, 2010.
  3. Invited talk entitled “Oxidative Stress and Mitochondria-Targeting Antioxidants” by EISAI at Mitochondrial Advisory Symposium held at Hatfield, London, September 13-15, 2010.
  4. Invited talk entitled “Mitochondrial Medicine for Cognitive Aging and Alzheimer’s Disease” by New York academy of Sciences and Alzheimer’s Drug Discovery Foundation held at New York on May 13, 2010.
  5. Invited talk entitled “Role of Amyloid Beta and Mitochondrial Dysfunction in Alzheimer’s Disease” at the Department of Neuroscience and Experimental Therapeutics, Texas A&M University College Station, TX February 11, 2010

2009

  1. Invited talk entitled “Mitochondrial Dysfunction in Aging and Alzheimer’s Disease” at the Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, November 30, 2009.
  2. Invited talk entitled “Amyloid beta, mitochondrial structural and functional dynamics in Alzheimer’ Disease” at the Gordon Research Conference on Molecular and Cellular Bioenergetics to be held at Proctor Academy, Andover, New Hampshire, June 7-12, 2009.

2008

  1. Invited talk entitled “Mitochondria in Aging and Alzheimer’s Disease” at the Neurology Department, Oregon Health and Science University, April 21, 2008.

2007

  1. Invited talk entitled “Amyloid beta and mitochondrial dysfunction in the development and progression of Alzheimer’s disease: implications for mitochondrial therapeutics” at 5th International Congress on VASCULAR DEMENTIA held at Budapest, Hungary November  8-11,    2007.
  2. Invited seminar entitled “Mitochondrial Dysfunction in Aging and Alzheimer’s disease: Strategies to Protect Neurons” at the Neuroscience and Neurology Department, Cornell University, New York, July 17-18, 2007.

2003

  1. Invited seminar on Alzheimer’s Disease entitled “Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial and apoptotic genes is an early cellular change in Alzheimer’s disease” at the Biology Department,       University of Oregon, Eugene            in October 2003.

2001

  1. Invited seminar on Alzheimer’s disease entitled “Gene expression profiles in Alzheimer’s disease patients” at the Oregon National Primate Research Center, Oregon Health Sciences University, April 17, 2001.

2000

  1. Invited seminar on “Gene expression profiles of transcripts in Alzheimer’s disease” at the Alzheimer’s disease Center, Oregon Health Sciences University, Portland, Oregon, on January 2000.

1999

  1. Invited seminar on Huntington’s disease entitled ‘Transgenic mouse models for Huntington’s disease: Mechanisms of neurodegeneration and psychosis’ at the Neurological Sciences Institute Oregon Health Sciences University, Portland, Oregon, on October 13, 1999.
  2. Invited seminar on Huntington’s disease entitled “In Vivo Models for Huntington’s disease” at the Sanders Brown Center on Aging, University of Kentucky, Lexington March 22, 1999.
  3. Invited seminar on Huntington’s Disease entitled “Mouse Models for Huntington’s disease” at the McLaughlin Research Institute, Great Falls, Montana on June 4, 1999.

 

Oral Presentations

Mao, P, Manczak M, Shree D and Reddy PH. Mitochondrial structural and functional changes caused by

amyloid beta in Alzheimer’s disease. Paper presented at International Conference onAlzheimer’s Disease held at Vienna, Austria July 11-16, 2009.

Reddy PH and Manczak M. Neuroprotection by mitochondrially targeted antioxidants in Alzheimer’                     disease. Paper presented at Neuroscience meeting held in Washington DC November 15-19                   2008.

Whetsell, Jr. WO Reddy PH, Charles V and Tagle DA (1999). Evaluation of Neuropathologic changes in            striatum and cerebral cortex of transgenic mice expressing full-length human cDNA: A new model          for Huntington’s disease. Paper presented at the Annual meeting of the American Association of       Neuropathologists held Portland, Oregon, June 17-20, 1999.

Reddy PH, Charles V, Ayoub J, Whetsell, Jr.,WO, Miller G and Tagle DA (1999). Characterization of Mouse Models for Huntington’s disease. Paper presented at 2nd International Conference on Unstable Microsatellites and Human Disease, Chapel Hill, North Carolina April 17-20, 1999.

Reddy PH, Williams M, Charles V, Whetshel Jr., WO, Garrett L, Buchanan LP, Miller G and Tagle, DA (1998). Selective neuronal loss and behavioural anomalies in HD transgenic mice expressing mutated full-length cDNA. Presented at Mouse Molecular Genetics, abstract no=327. Cold Spring Harbor Laboratory, New York, September 2-6, 1998.

Reddy PH, Williams M, Miller G, Glass M, Paylor R, Garrett L, Herkenham M, Crawley J and Tagle DA (1997). Transgenic mouse models for Huntington’s disease. Paper presented at 47th Annual meeting of American Society of Human Genetics held at Baltimore, Maryland October 28 – November 1 Vol 61, No 4 abstract no=274.

Reddy PH, Williams M, Miller G, Stockburger E and Tagle DA (1997). Transgenic mouse models for Huntington’s disease. Paper presented at Annual Scientific retreat of National Human Genome Research Institute August 19-20, 1997.

Reddy PH, Petrou M, Tiwary RS, Reddy PA and Modell B (1993). Hereditary anaemias and consanguinity among the tribal population of Central India. Paper presented at 5th International Conference on Thalassaemias and haemoglobinopathies held at Cyprus, March 29 – April 4. 1993.

Gupta RB, Pandey PL, Reddy PH, Kumar D, A Pathak and RS Tiwary. Hereditary anaemias and matting pattern among the Saharias (a tribal population) of Madhya Pradesh, India. Paper presented at 17th Annual meeting of Indian Society of Human Genetics held at Bhuvaneshwar, December 17-20, 1992.

Reddy PH, and Ghosh PK (1990). Spontaneous and chemically induced tissue specific differences in the frequency of in vivo sister chromatid exchange in Albino Swiss mice. Paper presented at 15th Annual conference of Indian Society of Human Genetics held at Madras January 18-20, 1990.

Reddy PH and Sekhar AC (1990). A genetic study of “Mala” population of Andhra Pradesh, India. Paper presented at 15th Annual conference of Indian Society of Human Genetics held at Madras January 18 – 20, 1990.

 

Poster Presentations in Reverse Chronological Order

 

2019

Kumar S, Reddy PA, Yin X and Reddy PH. Novel microRNA-455-3p and its protective effects against   abnormal APP processing and amyloid beta toxicity in Alzheimer’s disease. Poster presented at       the Annual Meeting of Society  for Neuroscience, Chicago, October 19-23, 2019

Vijayan M and Reddy PH (2019)  Novel microRNA PC-5P-12969 and ischemic stroke. Poster presented           at the Annual Meeting of Society  for Neuroscience, Chicago, October 19-23, 2019

Pradeepkiran JA and Reddy PH (2019) Structure based design and molecular docking studies for            phosphorylated tau inhibitors in Alzheimer’s disease. Poster presented at    the Annual Meeting of Society  for Neuroscience, Chicago, October 19-23, 2019.

2018

George E, Oliver D, and Reddy PH. Can Healthy Diets, Regular Exercise and Better Lifestyle Delay the            Progression of Dementia in Elderly Individuals?  Abstract submitted and poster presented at the   Regional Healthy Aging and Dementia Research Symposium held at Lubbock TX, October 24 &    25, 2018.

Oliver E, and Reddy PH. Mitochondria Targeted Molecules as Therapeutic Agents against Alzheimer’s   Disease. Abstract submitted and poster presented at the Regional Healthy Aging and Dementia      Research Symposium held at Lubbock TX, October 24 & 25, 2018.

Pradeepkiran JA, and Reddy PH. Whole transcriptome analysis dissecting the differential gene   expression profiles of Alzheimer’s disease samples with next generation sequencing method – RNA-Seq. Abstract submitted and poster presented at the Regional Healthy Aging and Dementia       Research Symposium held at Lubbock TX, October 24 &25, 2018.

Pradeepkiran JA, and Reddy PH. Structure based design and molecular docking studies for        phosphorylated tau inhibitors in Alzheimer’s disease. Abstract submitted and poster presented at          the Regional Healthy Aging and Dementia Research Symposium held at Lubbock TX, October 24  & 25, 2018.

Pradeepkiran JA, Yin X, Reddy PA, Manczak M and Reddy PH. Protective Effects of BACE1 Inhibitory            Ligand Against Amyloid Beta-Induced Synaptic and Mitochondrial Toxicities in Alzheimer’s           Disease. Abstract submitted and poster presented at the Regional Healthy Aging and Dementia      Research Symposium held at Lubbock TX, October 24 & 25, 2018.

Reddy PA and Reddy PH. Ignored Brain Region ‘The Brainstem’ in the Progression and Pathogenesis of            Alzheimer’s Dementia: Gender-Based Data from Human and Rhesus Macaques. Abstract           submitted and poster presented at the Regional Healthy Aging and Dementia Research         Symposium held at Lubbock TX, October 24 & 25, 2018.

Vijayan M, Kumar S, Cengiz P, Karamyan VT and Reddy PH. Expression level of novel miRNA PC-5P 12969 in two different in vivo stroke models. Abstract submitted and poster presented at the           Regional Healthy Aging and Dementia Research Symposium held at Lubbock TX, October 24 &    25, 2018.

Kumar S, Vijayan M Reddy PA, Yin X and Reddy PH. MicroRNA-455-3p regulates amyloid precursor    protein processing, mitochondrial biogenesis and synaptic activity in Alzheimer’s disease. Abstract submitted and poster presented at the Regional Healthy Aging and Dementia Research   Symposium held at Lubbock TX, October 24 & 25, 2018.

Arandia G and Reddy PH. Alzheimer’s disease and other Dementias: Review of Epidemiological Data    and Promising Interventions. Abstract submitted and poster presented at the Regional Healthy            Aging and Dementia Research Symposium held at Lubbock TX, October 24 & 25, 2018.

Kandimalla R, Manczak M, Yin X and Reddy PH. Abnormal Mitochondrial Dynamics and Defective       Synapses: Protective Role of Reduced Dynamin-related protein 1 in Alzheimer’s Disease.      Abstract submitted and poster presented at the Regional Healthy Aging and Dementia Research   Symposium held at Lubbock TX, October 24 & 25, 2018.

Manczak M, Kandimalla R, Yin X, Vijayan M, Kurvva CS, Kumar S, Reddy PH. Reduced dynamin        related            protein 1 mitigates mitochondrial fragmentation, elevates spatial learning and memory      functions and elevates dendritic spines in APP transgenic mice. Abstract submitted and poster   presented at the Regional Healthy Aging and Dementia Research Symposium held at Lubbock           TX, October 24 & 25, 2018.

Willms J, Ramasubramanian R, Sawant N and Reddy PH. Protective Effects of DDQ Against Mutant    Huntingtin-induced Mitochondrial and Synaptic Toxicities in Huntington’s Disease Striatal       Neurons.  Abstract submitted and poster presented at the Regional Healthy Aging and Dementia        Research Symposium held at Lubbock TX, October 24 & 25, 2018.

Yin X, Reddy AP, Kumar S and Reddy PH. Protective Role of Citalopram Against Amyloid Beta-induced            Mitochondrial, Autophagy and Synaptic Toxicities in Alzheimer’s Disease. Abstract submitted and            poster presented at the Regional Healthy Aging and Dementia Research Symposium held at       Lubbock TX, October 24 & 25, 2018.

Ramasubramanian B, Burugu D, Yin X, Boles AN and Reddy PH. Analysis of Blood-based Biomarkers  to Detect Cognitive Decline Among The Residents of Rural West Texas – Project FRONTIER         Data. Abstract submitted and poster presented at the Regional Healthy Aging and Dementia Research Symposium held at Lubbock TX, October 24 & 25, 2018.

Lopez V, Boles AN, Reddy PH. An Assessment – Texas Healthy Communities Program. Abstract          submitted and poster presented at the Regional Healthy Aging and Dementia Research         Symposium held at Lubbock TX, October 24 & 25, 2018.

Boles AN, Reddy PH, PhD, Lopez V, Arandia G, PhD, Carrasco R, Aguirre C. Project FRONTIER: Study            Protocol. Abstract submitted and poster presented at the Regional Healthy Aging and Dementia   Research Symposium held at Lubbock TX, October 24 & 25, 2018.

Lopez V, Thompson S, Boles AN, MS, Carrasco R, Aguirre C, Blackmon J, Reddy PH. Healthy Lubbock            Workshops.  Abstract submitted and poster presented at the Regional Healthy Aging and  Dementia Research Symposium held at Lubbock TX, October 24 & 25, 2018.

Boles AN, Lopez V, Ament C, Blackmon J, Thompson S and Reddy PH. TTUHSC Garrison Institute on Aging – Community Outreach Programs Healthy Lubbock Programs. Abstract submitted and       poster presented at the Regional Healthy Aging and Dementia Research Symposium held at         Lubbock TX, October 24 & 25, 2018.

Ament C, Boles AN, MS, Blackmon J and Reddy PH. Lubbock Retired & Senior Volunteer Program.     Abstract submitted and poster presented at the Regional Healthy Aging and Dementia Research    Symposium held at Lubbock TX, October 24 & 25, 2018.

Bass K and Reddy PH. The lysosomal-mitochondrial axis and neurodegeneration in Alzheimer’s disease: dissecting molecular mechanisms. Abstract submitted and poster presented at the     Regional Healthy Aging and Dementia Research Symposium held at Lubbock TX, October 24 &    25, 2018.

Kumar S and Reddy PH. MicroRNA-455-3p as a potential peripheral biomarker and therapeutic target   for Alzheimer’s disease. Oral abstract submitted and presented at the Regional Healthy Aging           and Dementia Research Symposium held at Lubbock TX, October 24 & 25, 2018.

Vijayan M and Reddy PH. Novel microRNA PC-5P-12969 as Potential Peripheral Biomarker for Ischemic            Stroke. Oral abstract submitted and presented at the Regional Healthy Aging and Dementia         Research Symposium held at Lubbock TX, October 24 & 25, 2018.

Arandia G and Reddy PH. The Impact of Chronic Diseases on Aging: a look at epidemiology, risk           factors, and programmatic efforts for chronic disease prevention. Oral abstract submitted and      presented at the Regional Healthy Aging and Dementia Research Symposium held at Lubbock          TX, October 24 & 25, 2018.

2017

Manczak M, R Kandimalla, Yin X, Vijayan M, Kuruva CS, Kumar S and Reddy PH (2017) Reduced       dynamin-related protein 1 mitigates mitochondrial fragmentation, elevates spatial learning and         memory functions and elevates dendritic spines in APP mice. Abstract submitted and poster         presented at the Annual Meeting of Society for Neuroscience held at Washington DC, November         11-16, 2017.

Kandimalla R, Manczak M, Yin X, Vijayan M, Kuruva CS, Kumar S and Reddy PH (2017)  A partial loss            of dynamin-related protein 1 enhances dendritic spines, reduces fragmented mitochondria and        increases hippocampal based cognitive function in mutant Tau mice Abstract submitted and poster presented at the Annual Meeting of Society for Neuroscience held at Washington DC,         November 11-16, 2017.

Kuruva CS, Manczak M, Yin X, Ogunmokun G, Reddy PA and Reddy PH (2017) Aqua-Soluble DDQ    Reduces the levels of Drp1 and Amyloid Beta and Inhibits Abnormal Interactions of Amyloid Beta   and Dynamin Related protein. Abstract submitted and poster presented at the Annual Meeting of Society for Neuroscience held at Washington DC, November 11-16, 2017.

Bhatti JS, Tamarai K, Pradeepkiran AJ, and Reddy PH (2017) Oxidative stress and mitochondrial          dysfunction in TALLYHO/JngJ mice – a common link between type 2 diabetes, obesity and     Alzheimer’s disease. Abstract submitted and poster presented at the Annual Meeting of Society    for Neuroscience held at Washington DC, November 11-16, 2017.

Vijayan M, Kumar S and Reddy PH (2017) Identification of novel circulatory microRNA signatures linked           to patients with stroke. Abstract submitted and poster presented at the Annual Meeting of Society    for Neuroscience held at Washington DC, November 11-16, 2017.

Kumar S, Vijayan M and Reddy PH (2017) MicroRNA-455-3p as a potential peripheral biomarker for     Alzheimer’s disease. Abstract submitted and poster presented at the Annual Meeting of Society           for Neuroscience held at Washington DC, November 11-16, 2017.

Pradeepkiran JA and Reddy PH (2017) Pharmacophore based screening and molecular docking probing          the novel inhibitors against BACE1 of Alzheimer’s disease. Abstract submitted and poster       presented at the Annual Meeting of Society for Neuroscience held at Washington DC, November   11-16, 2017.

Reddy PA, Yin X, Manczak M, Ogunmokun G, Bethea C and Reddy PH (2017) Mutant APP and Tau    Toxicities in Serotonergic and Non-serotonergic Neurons and Protective Effects of Citalopram.           Abstract submitted and poster presented at the Annual Meeting of Society for Neuroscience held   at Washington DC, November 11-16, 2017.

Williams J, Smith F, Kumar S, Vijayan M and Reddy PH (2017) Differential expression of microRNAs in            the skeletal muscles of mice with aging, Poster to be presented to the 29th Annual Student     Research Week, March 7-10, 2017.

Smith F, Williams J, Kumar S, Vijayan M and Reddy PH (2017) Upregulation of microRNAs in the brains           of mice with aging, Poster to be presented to the 29th Annual Student Research Week, March          7-10, 2017.

Aquino A, Anya A, Jacob A, Mende S, Boles A, Khan HM, Reddy PH (2017) Coronary Heart Disease in            Rural West Texas, Poster to be presented to the 29th Annual Student Research Week, March      7-10, 2017.

2016

Boles AN, Khan H, Lenzmeier TA, Molinar-Lopez, VA, Ament JC, TeBrink KL, Stonum K, Gonzales RM,            Reddy PH (2016) Impact of Exercise and Education in Adults of Lubbock, Texas: Implications for            Better Lifestyle. Poster presented to the 28th Annual Student Research Week, March 8-11, 2016.

Mitchell A, Grady MK, Yin X, Manczak M and Reddy PH (2016) Glycogen Synthase Kinase 3b Inhibitor,           IM-12 Protects Against Amyloid Beta, Synaptic and Mitochondrial Toxicities in Alzheimer’s    Disease Neurons. Abstract submitted to 28th Annual Student Research Week, March 8-11, 2016

Reddy PA, Manczak M, Yin X, Reddy PH (2016) Protective Effects of Selective Serotonin Reuptake    Inhibitors and Neurosteroids Against Alzheimer’s Disease Neurons. Abstract submitted to     Alzheimer’s Association International Conference, July 24-28, 2016, Toronto, Canada.

2015

Reddy PH, Manczak M, Kandimalla R, Yin X, Pandey AK, Kuruva CS, (2015) Synaptic Gene Expression            Analysis of Autopsy Brains From Garrison Institute on Aging Brain Bank: Eva-Green Biochemistry            Based Real-time RT-PCR Detects mRNA levels Better Than Sybr-Green. Abstract submitted to the Annual Meeting of Society for Neuroscience to be held at Chicago October 17-21, 2015.

Yin X, Manczak M, Kandimalla R, AK Pandey, CS Sekhar, S Yeguvapalli, and Reddy PH (2015)            Mitochondrial Division Inhibitor 1 and Mitochondria-Targeted Molecules MitoQ and SS31 Protects            Against Mutant Htt-induced Mitochondrial toxicities in Huntington’s Disease Neurons. Abstract     submitted to the Annual Meeting of Society for Neuroscience to be held at Chicago October 17        21, 2015.

Manczak M, R Kandimalla, Pandey AK, Yin X, Kuruva CS, Yegavapalli S, Fry D, Osborn C and Reddy PH (2015) Reduced Dynamin-related Protein 1 Protects Against Amyloid Beta, Mitochondrial            Toxicities and Synaptic Damage in Alzheimer’s Disease. Abstract submitted to the Annual  Meeting of Society for Neuroscience to be held at Chicago October 17-21, 2015.

Kandimalla R, Manczak M, Pandey AK, Yin X, Kuruva CS, Yegavapalli S, Fry D, Osborn C and Reddy PH Reduced Dynamin-related Protein 1 Protects Against Phosphorylated Tau, Mitochondrial Dysfunction and Synaptic Damage in Alzheimer’s Disease. Abstract submitted to the Annual  Meeting of Society for Neuroscience to be held at Chicago October 17-21, 2015.

Reddy PH and Manczak M (2015) ‘Mitochondrial division inhibitor 1 protects against mutant huntingtin    induced mitochondrial dynamics and neuronal damage in Huntington’s disease’, Translational        Science 2015, Washington, D.C., April 2015.

2014

Manczak M, Reddy PH. RNA silencing of genes involved in Alzheimer’s disease enhances mitochondrial            function and synaptic activity. Poster Presented at Research, OHSU Week, May  2014.

Mao P, Manczak M, Shirendeb UP, Reddy PH. MitoQ, a mitochondria-targeted antioxidant, delays        disease progression and alleviates pathogenesis in an experimental autoimmune    encephalomyelitis mouse model of multiple sclerosis. Abstract submitted to present a poster at Research Week, May 2014.

2013

Shirendeb UP, Calkins MJ, Manczak M, Anekonda V, Dufour B, McBride JL, Mao P and Reddy PH.                 Mutant huntingtin’s interaction with mitochondrial protein, Drp1 impairs mitochondrial biogenesis  and causes defective axonal transport and synaptic degeneration in Huntington’s disease.        Poster presented at Research Week, OHSU, May 2013.

Manczak M, Reddy PH. Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau        causes mitochondrial dysfunction in Alzheimer’s disease. Abstract submitted to present the           poster at Research Week, OHSU, May 2013.

Manczak M, Reddy PH. Abnormal interaction of oligomeric amyloid beta with phosphorylated tau:            Implications to neuronal damage and synaptic dysfunction in Alzheimer’s disease. Poster presented at Research Week, OHSU, May 2013.

2012

Manczak M, Calkins MJ, Reddy PH. Impaired mitochondrial dynamics and abnormal  interaction           of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer’s       disease: implications for neuronal damage. Poster presented at Research Week,         OHSU, May    10-12,  2012.

Reddy TP, Manczak M, Calkins MJ, Mao P, Reddy AP, Shirendeb U, Park B, Reddy PH. Toxicity         of neurons treated with herbicides and neuroprotection by mitochondria-targeted antioxidant   SS31.  Poster presented at Research Week, OHSU, May 10-12,            2012.

Shirendeb U, Reddy AP, Manczak M, Calkins MJ, Mao P, Tagle DA, Reddy PH. Abnormal        mitochondrial            dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington’s        disease: implications for selective neuronal damage. Poster presented at Research Week,   OHSU, May 10-12, 2012.

Calkins MJ, Manczak M, Mao P, Shirendeb U and Reddy PH. Impaired mitochondrial biogenesis,          defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic  degeneration in a mouse model of Alzheimer’s disease. Poster presented at Research Week,  OHSU, May 10-12, 2012.

Mao P, Manczak M, Calkins MJ, Troung Q, Reddy TP, Reddy AP, Shirendeb UP, Lo HH, Rabinovitch,  Reddy PH (2012) Mitochondria-targeted catalase reduces abnormal APP processing, amyloid           beta production, and BACE1 in a mouse model of Alzheimer’s disease: Implications for  neuroprotection and lifespan extension. Poster presented at Research Week, OHSU, May 10-12,   2012.

2010

Reddy PH and Manczak M (2010). Differential expression of mitochondrial structural and amyloid beta  related            genes in Alzheimer’s disease patients: implications to neuronal damage and cognitive       decline. Poster presented at the 40th Annual Meeting of the Society for Neuroscience held at San Diego November 13-17, 2010.

Manczak M and Reddy PH (2010). Abnormal interaction of Drp1 with amyloid beta in neurons from       Alzheimer’s disease patients: Implications for mitochondrial fragmentation and neuronal damage.        Poster  presented at the 40th Annual Meeting of the Society for Neuroscience held at San Diego     November 13-17, 2010.

Reddy TP, Calkins M, Manczak M, Mao P, Reddy AP and Reddy PH (201). Neuronal toxicity of            pesticides and neuroprotection by mitochondrially targeted antioxidant SS31. Poster presented at     the 40th Annual Meeting of the Society for Neuroscience held at San Diego November 13-17,  2010.

Mao P, Manczak M, Calkins MJ, Reddy AP, Rabinovich P and Reddy PH (2010). The effects of            mitochondrially targeted catalase on amyloid beta pathology and mitochondrial function in            amyloid beta precursor-protein transgenic mice. Poster presented at the 40th Annual Meeting of    the Society for Neuroscience held at San Diego November 13-17, 2010.

Calkins MJ, Manczak M, Mao P, Shirendeb U, Protter AA and Reddy PH (2010). Synaptic and  mitochondrial protection by Dimebon in primary neurons from amyloid beta precursor protein     transgenic mice. Poster presented at the 40th Annual Meeting of the Society for Neuroscience        held at San Diego November 13-17, 2010.

Shirendeb U, Reddy AP, Calkins MJ, Manczak M, Mao P and Reddy PH (2010). Differential expression            of mitochondrial structural genes in brain tissues from Huntington’s disease patients: Implications     for abnormal mitochondrial dynamics and selective neuronal damage Poster presented at the 40th        Annual Meeting of the Society for Neuroscience held at San Diego November 13-17, 2010.

2009

Reddy PH, Mao P, Manczak M, Rabinovitch P, Searles R and Reddy AP (2009). Mitochondrially           targeted catalase increases the mRNA expression of neuroprotective genes and decreases           amyloid beta toxicity: Evidence from a global gene expression study. Poster presented at the 39th           Annual Meeting of the Society for Neuroscience held at Chicago, Ill, October 17-21, 2009.

Aliev G, Manczak M, Grant KA, and Reddy PH (2009). Mitochondrial damage as a hallmark for liver and            neuronal lesions during chronic ethanol self administration in cynomolgus monkeys. Poster          presented at the 39th Annual Meeting of the Society for Neuroscience held at Chicago, Ill,     October 17-21, 2009.

Reddy AP, Manczak M, McCue MM, Mao P, Grant KA and Reddy PH (2009). Abnormal mitochondrial and longevity gene expression changes in ethanol self-administered cynomolgus monkeys.    Poster  presented at the 39th Annual Meeting of the Society for Neuroscience held at Chicago, Ill,   October 17-21, 2009.

Mao P, Gallagher P, Nedungadi S, Kohama SG, Ferguson B, and Reddy PH (2009). Mitochondrial DN              deletions and differential mitochondrial DNA content in Rhesus monkeys: Implications for aging.  Poster            presented at the 39th Annual Meeting of the Society for Neuroscience held at Chicago, Ill,            October 17-21, 2009.

Manczak M (2009), Mao P, Nakamura K, Bebbington C, Park B and Reddy PH (2009). Neutralization of            granulocyte macrophage colony stimulating factor decreases amyloid beta 1-42 and suppresses microglial activity in a transgenic mouse model of Alzheimer’s disease. Poster presented at the        39th  Annual Meeting of the Society for Neuroscience held at Chicago, Ill, October 17-21, 2009.

2008

Reddy PH, Manczak M and Zhao W (2008) Mitochondrially targeted antioxidant therapeutics                  in Alzheimer’s disease. Poster presented at 11th International Conference on Alzheimer’       disease            Chicago, July 30, 2008.

Manczak M, Denmark D, Buckb KJ and Reddy PH. Mitochondrial fission and fusion imbalance in ethanol            treatment.  Poster presented at Neuroscience meeting, Washington DC – November 15-19, 2008.

Mao P, Reddy PH and Thuillier P (2008) Cellular protection of cocaine and amphetamine regulate                      transcript via its antioxidative property in human cells. Abstract submitted to American Heart                    Association meeting to be held in Louisiana, New Orleans –November 8-11, 2008.

2006

Anekonda TS, Manczak M, Park BS , Henson E, Quinn Q and Reddy PH (2006) Mitochondria are a      direct site of Ab accumulation in Alzheimer’s disease: implications for free radical generation and     oxidative damage in disease progression. Poster presented at 37th Annual meeting of American            Society of Neurochemistry held at Portland, Oregon. March 11-16, 2006.

2004

Reddy PH, Gutala R, Mani G, Murdoch G, Kaye JA, Tagle DA, Yang R (2004). Role of cytoskeletal       protein            Synaptopodin in late-onset Alzheimer’s disease patients. Poster presented at the 57th        Annual Scientific Meeting of Gerontological Society of America (Reddy et al 2004 Abstract #6.42)   held at Washington DC November 19-23, 2004.

Manczak M, Park BS, Jung Y, Partovi D and Reddy PH (2004). Differential expression of oxidative            phosphorylation genes in patients with Alzheimer’s disease: Implications for early  mitochondria               dysfunction and oxidative damage.  Poster presented at the 32nd Annual Meeting of the Society              for Neuroscience held at San Diego October 23-27, 2004.

Reddy PH, Manczak M, Partovi D, Jung Y and Park BS (2004). Age-related Mitochondrial Gene            Expressions In Mice: Implications to Mitochondrial Dysfunction and Oxidative Dame in Aging      Brain. Poster presented at the 32nd Annual Meeting of the Society for Neuroscience held at San Diego October 23-27, 2004.

Reddy PH, McWeeney S, Park BS, Manczak M, Gutala RV, Jung Y, Yau V, Searles R, Mori M and      Quinn J (2004). Gene expression Profiles of Amyloid Precursor Protein Transgenic Mice: Up        regulation of Mitochondrial Metabolism and Apoptotic Genes Is an Early Cellular Change in     Alzheimer’s disease. Poster presented at the 9th International Conference on Alzheimer’s disease      and related disorders held at Philadelphia July 17-22, 2004.

Reddy PH, Manczak M, Partovi D, Y Jung Y (2004). Up-regulation of mitochondrial genes in the brains  of amyloid precursor protein transgenic mice and Alzheimer’s disease patients: implications for          early mitochondrial dysfunction and oxidative damage. Poster presented at the Mitochondria and        Neuroprotection Symposium held at Ft. Lauderdale, FL, April 16-19, 2004.

2002

Mani G, Gutala R, Murdoch G, Whetsell Jr WO,  Kaye JA and Reddy PH (2002). Differential Loss of     Synaptic Elements in Alzheimer’s disease.  Poster Presented at the 32nd Annual Meeting of the       Society for Neuroscience (#748.12) held at Orlando, Florida., 2-7 November 2002.

Gutala R, Mani G, Yang R, Kaye JA and Reddy PH (2002). Down-regulation of the Synaptopodin Gene            in Alzheimer’s disease. Poster Presented at the 32nd Annual Meeting of the Society for                                 Neuroscience  (#748.12) held at Orlando, Florida., 2-7 November 2002.

Reddy PH, Quinn J, Gutala R, Mani G, Reddy PA, Kaye JA (2002). Gene Expression Profiles in Amyloid            Precursor Protein Transgenic Mice. Poster Presented at the 32nd Annual Meeting of the Society              for Neuroscience (#748.12) held at Orlando, Florida., 2-7 November 2002.

2001

Reddy PH, Yang R, Murdock G, Kaye JA and Mani G (2001). Role of cytoskeletal protein Synaptopodin           in late onset Alzheimer’s disease Pathogenesis. Poster presented at the 31st Annual meeting of        Neuroscience to be held in San Diego November 10-15 2001.

Seatorov VV, Charles V, Reddy PH, Tagle DA and Chuang DM. Abnormal Expression of            Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) in a Transgenic Mouse Model of      Huntington’s disease. Poster presented at the 31st Annual meeting of Neuroscience to be held in          San Diego November 10-15 2001.

2000

Reddy PH, Teng S, Manickam P, Yu P, Khan J, Runyons C, Zahorchak R, Markesbery W,        Elkahloun A and Tagle DA (2000). Differential Expression of Genes in Alzheimer’s disease. Poster  presented at the 30th Annual meeting of Neuroscience held at New Orleans, Louisiana    November 4-9, 2000, QQ-34: 83.4

Guidetti P, Reddy PH, Tagle DA and Schwarcz R (2000).  Early Kynurenergic impairment in       Huntington’s disease and in atransgenic mouse model. Poster presented at the 30th Annual       meeting of Neuroscience held at New Orleans, Louisana November 4-9, 2000, QQ-26: 480.10.

Young T, Mezey E, Reddy PH, Dehejia A, Charles V, Polymeropoulos MH, Brownstein MJ, and            Tagle DA (2000). Alpha-synuclein immunoreactivity of Huntington polyglutamine aggregates in        striatum and cortex of Huntington’s disease patients and transgenic mouse models. Poster           presented at the 30th Annual meeting of Neuroscience held at New Orleans, Louisana November     4-9, 2000 QQ38:578.12.

1999

Reddy PH, Charles V, Williams M, Ayoub J, Whetsell Jr. WO, Miller G and Tagle DA (1999). Analysis of            transgenic mouse models for Huntington’s Disease. Poster presented at 18th International meeting of the World Federation of Neurology Research Group on Huntington’s disease and 13th International meeting of the International Huntington’s  Association held in Kurhaus Hotel, The   Hague, Netherlands. 28th August to 2nd  September 1999.

Reddy PH, Charles V, Ayoub J, Williams M, Miller G, Whetsell Jr. WO, and Tagle DA (1999). Behavioral           and neuropathological abnormalities in transgenic mouse models for Huntington’s disease.      Poster presented at Gordon Research Conference on Human Molecular Genetics at Salve                  Regina University, Newport, Rhode Island, August 8-13, 1999.

Reddy PH, Charles V, Ayoub J, Williams M, Miller G, Whetsell Jr. WO, and Tagle DA (1999). Sequences            flanking mutant polyglutamine repeat may play a role in selective neuronal loss. Poster presented            at the 29th Annual meeting of Society for Neuroscience held in Miami, Florida October 23-28,          1999.

Tagle DA, Charles V, Ayoub J, Romantseva L, and Reddy PH (1999). Behavioral analyses of full-length            (1-67 exons) and truncated (1-3 exons) transgenic mouse models for Huntington’s disease.  Poster  presented at the 29th Annual meeting of Society for Neuroscience held in Miami, Florida      October 23-28, 1999.

Whetsell, Jr. WO, Charles V, Reddy PH, and Tagle DA (1999). Neuropathological changes in the            striatum and cerebral cortex of transgenic mice expressing full-length huntingtin protein. Poster     presented at the 29th Annual meeting of Society for Neuroscience held in Miami, Florida October           23-28, 1999.

Charles V, Reddy PH, Whetsell Jr. WO, Ayoub J, and Tagle DA (1999).  Neurochemical and      morphological            changes in Huntington’s disease transgenic mice expressing mutated full-length    huntingtin protein. Poster presented at the 29th Annual meeting of Society for Neuroscience held      in Miami, Florida October 23-28, 1999.

Guidetti P, Charles V, Reddy PH, Ayoub J, Schwarcz R and Tagle DA (1999). Mitochondrial energy      metabolism in a full-length cDNA transgenic model of Huntington’s disease. Poster       presented at the 29th Annual meeting of Society for Neuroscience held in Miami, Florida October     23-28, 1999.

Chen EY, Charles V, Reddy PH, Tagle DA and Kordower JH (1999). Intermediate stage heterozygote    mice with expanded CAG repeats do not display a loss of striatal neurons. Poster presented at         the 29th Annual meeting of Society for Neuroscience held in Miami, Florida October 23-28, 1999.

Charles V, Guidetti P, Reddy PH, Ayoub J, Schwarcz R and Tagle DA (1999). Examination of energy    metabolism defects in full-length cDNA transgenic model of Huntington’s disease. Poster         presented at the 29th Annual meeting of Society for Neuroscience held in Miami, Florida October           23-28, 1999.

1998

Reddy PH, Williams M, Wangsa D, Ried T and Tagle DA (1998). A novel human chromosome 9 specific            alpha   satellite sequence. Poster presented at 48th Annual meeting of the American Society of    Human            Genetics, Denver, Colorado. October 28 – November 1, 1998, Vol 63, 4, abstract no=837.

Kim, M, Laforet G, Lee HS, Chang P, McIntyre C, Martin EM, Kim TW, Williams M, Reddy PH, Tagle DA,            Boyce FM, Won LA, Heller A, Aronin N and DiFiglia M (1998). Mutant huntingtin expression in            immortalized striatal neurons and the effect of caspase inhibitors. Poster presented at the 28th      Annual meeting of Society for Neuroscience. Poster 379.2, Los Angeles, CA, November 7-12,     1998.

Laforet GA, Lee HS, Cadigan B, Chang P, Chase KO, Sapp E, Martin EM, McIntyre C, Williams M,        Reddy PH, Tagle DA, Stein JS, Boyce FM, DiFiglia M, and Aronin N. Development and          characterization of a novel transgenic model of Huntington’s disease which recapulates features         of the human illness. Poster presented at 28th Annual meeting of Society for Neuroscience                 Poster no=380.8 Los Angeles, CA November 7-12, 1998.

Reddy PH , Williams M, Wangs A, Ried T and Tagle DA (1998). A novel human chromosome 9 specific            alpha   satellite sequence. Poster presented at 5th Annual Scientific retreat of National Human     Genome Research Institute, held at Airlie Center, Airlie, Virginia, September 17-18, 1998.

Reddy PH, Williams M, Charles V, Garrett L, Romantseva L,  Buchanan LP, Whetsell Jr., WO, Miller G and DA Tagle DA (1998) . Selective neuronal loss and behavioral abnormalities in mutated full      length  Huntington’s disease transgenic mice. Poster presented at 5th Annual scientific retreat of           National Human Genome Research Institute, held at Airlie Center, Airlie, Virginia, September 17-       18, 1998.

Mosbrook DM, Reddy PH, Williams M, Sorenson SA and Tagle DA (1998). Towards Identification of      autosomal dominant pure spastic paraplegia (ADSP) in chromosome 2p21-24. Poster presente                     at 5th Annual scientific retreat of National Human Genome Research Institute, held at Airli                      Center, Airlie, Virginia, September 17-18, 1998.

Charles V, Reddy PH, Williams M, Romantseva L and Tagle DA (1998). Molecular and   Neuropathological changes in transgenic mouse model for Huntington’s Disease. Poster         presented at 5th Annual scientific retreat of National Human Genome Research Institute, held at       Airlie Center, Airlie, Virginia, September 17-18, 1998.

1997

Liu YF, Reddy PH, Buchanan LP, Deth R, Zon L and Tagle DA (1997). Expression of the huntingtin        mutant            activates JNK/SAPK and induces neuronal apoptosis. Poster presented at 27th Annual      meeting of Society for Neuroscience, New Orleans, LA, October 25-30, 1997.

1996

Reddy PH, Stockburger E, Wilderson J, Ellison J, Gillevet P and Tagle DA (1996).  Oligo capture and            characterization of CAG repeat containing cDNAs from adult human brain. Poster presented at   6th Annual meeting of American Society of Human Genetics held at San Francisco, CA, and October 29-November 2, 1996. Poster 1626, Vol 59, 4.

Reddy PH, Buchanan LP and Tagle DA (1996). Generation of transgenic mice for Huntington’s Disease.            Poster  presented at scientific retreat of National Center for Human Genome Research held at     Airlie, Virginia, and September 11-12, 1996.

1995

Reddy PH, Buchanan LP and Tagle DA (1995). Towards the development of a YAC transgenic mouse  model  for Huntington’s Disease. Poster presented at scientific retreat of National Center for  Human            Genome Research held at Airlie, Virginia September 12-13, 1995.

Kaeda JS, Chotray GP, Reddy PH, Stevens D, Britt RP, Vulliamy T, Luzzatto L and Mason PJ (1995).   Molecular genetics of G6PD deficiency in India. Poster presented at the Annual scientific meeting    of British Society of Haematology, Brighton, UK, April 3-April 6, 1995. British Journal of Haematology  vol 89, supplement 1.

1993

Reddy PH and Modell B (1993). Population genetics of aboriginal population “the Baiga” of Madhya        Pradesh, India. Poster presented at the postgraduate student exhibition at University College           London (UCL), London June 24, 1993.

Petrou M, Reddy PH, Fitches A and Old JM (1993). Alpha Thalassaemias and the Beta S in the Baiga   tribe of            central India. Poster presented at 5th International conference of Thalassaemias and            Haemoglobinopathies held at Cyprus March 29-April 4, 1993.

 

Research Mentor of Thesis For Undergraduates – Oregon Health and Science University

  1. Research mentor of Youngsin Jung from University of Portland for her B.S., Honors Senior Thesis “Mitochondrial Gene Expression in the Cortex of C57BL6 Mice During Aging. Spring 2004.

 

  1. Research Mentor of Chelsey Kline from Pacific University for her B.S., Honors Senior Thesis “Mitochondrial Fission and Fusion Effects of Ethanol Treated Human Hepatocytes” Spring 2008.

 

Mentoring

High School

  1. Sahil Tonk, TTUHSC Garrison Institute on Aging, March 2016 to August 2018

 

Undergraduate Intern

  1. Kate TeBrink, TTUHSC Garrison Institute on Aging, September 1, 2015 – 2018
  2. Gilbert Ogunmokun, TTUHSC Garrison Institute on Aging, June 1, 2016 – 2018

 

Medical Research Technicians/Volunteers

  1. Carrah Osborn, Medical Research Tech III, Garrison Institute on Aging Lubbock, Texas, March 2015 – August 2016
  2. David Fry, BS., Medical Research Tech, Garrison Institute on Aging Lubbock, Texas, March 2015 – March 2016
  3. Neha Sawant, MS., Medical Research Tech III, Garrison Institute on Aging Lubbock, Texas, February 2018 – Present
  4. Divya Burugu, MS., Medical Research Tech III, Garrison Institute on Aging Lubbock, Texas, May 2018 – 2019
  5. Elizabeth George, B.S. Volunteer Researcher, Garrison Institute on Aging Lubbock, Texas, September 2018 – Present

 

Masters in Public Health Student –GSBS 2015-2016

  1. Taylor Lenzmeier, TTUHSC Garrison institute on Aging, Research Student Community Outreach and

Education, May 2015 – 2016

 

Masters in Public Health Students – GSBS -2016-2017 TTUHSC

  1. Sarah Mende, MPH student – mentored for practicum/thesis
  2. Alejandro Aquino, MPH student – mentored for practicum/thesis
  3. Anthony Anya, MPH student – mentored for practicum/thesis
  4. Alexander Jacob, MPH student – mentored for practicum/thesis

 

Maters in Biology students – TTU/TTUHSC Collaboration

  1. Kavya Thamarai, MS- Biotech student – 2017-2018
  2. Christopher Hornbeck, MS Biotech Student, TTUHSC – 2018-2019
  3. Darryll Oliver, MS/PhD Student, TTUHSC 2018-2019

 

Mentoring Ph.D. and M.D./Ph.D. Student(s) – Texas Tech University Health Sciences Center

  1. Ravi Rajmohan (MD/PhD student) TTUHSC Garrison institute on Aging, January 2011 – 2016, completed Ph.D (published 3 articles with me in high impact factor journals)
  2. Josh Wilms, (MD/PhD student) TTUHSC Garrison institute on Aging (2018-2019)
  3. Kevin Bass, MD/PhD student for his PhD thesis (2018-2019)
  4. Breanne Williams for her Ph.D. (2018-2019)

 

Medical Interns

  1. Andrew Mitchell, B.S., (year 3 medical) TTUHSC Garrison Institute on Aging, July 2015 – 2017
  2. Mary Katherine Grady, B.S., (year 3 medical) TTUHSC Garrison Institute on Aging July 2015 – 2017
  3. Justin Williams, B.S. (year 2 medical) TTUHSC Garrison Institute on Aging February 2016 to 2017
  4. Flint Smith, B.S. (year 2 medical) TTUHSC Garrison Institute on Aging February 2016 to 2017
  5. Jake Smith B.S. (year 1 medical) TTUHSC Garrison Institute on Aging February 2017 to August 2018
  6. Marcus Hudson B.S. (year 1 medical) TTUHSC Garrison Institute on Aging February 2017 to 2018
  7. Nanna Amakiri, B.S. (year 1 medical) TTUHSC Garrison Institute on Aging February 2018 to 2019
  8. James Tran, B.S. (year 1 medical) TTUHSC Garrison Institute on Aging February 2018 to 2019
  9. Aron Kubosumi, B.S. (year 1 medical) TTUHSC Garrison Institute on Aging February 2018 to 2019

 

 

Research Associate

  1. Xiangling Yin, M.S, TTUHSC Garrison Institute on Aging, 2015 – 2015.

 

Postdoctoral Research Associates

  1. Pradeepkiran., TTUHSC Garrison Institute on Aging and Internal Medicine, 2016 – Present
  2. Murali Vijayan, Ph.D., TTUHSC Garrison Institute on Aging and Internal Medicine 2015 – Present
  3. Subodh Kumar, Ph.D., TTUHSC Garrison Institute on Aging and Internal Medicine, 2015 – Present
  4. Bhagvathi Ramachandran, TTUHSC Garrison Institute on Aging and Internal Medicine 2018-Present
  5. Chandra Kuruva, Ph.D., TTUHSC Garrison Institute on Aging 2015 -2017

 

Visiting Scientist

  1. Suneetha, Ph.D., Indian Council of Research Fellow, India – March 2016 – May 2016
  2. Jasvinder Bhatti, Ph.D., CV Raman Fellow, India – August 2016- August 2107

 

Senior Research Associates

  1. Rui Wang, Ph.D., TTUHSC Garrison Institute on Aging, 2015 –2017
  2. Xiangling Yin, M.S, TTUHSC Garrison Institute on Aging, 2015 – present
  3. Maria Manczak, Ph.D., TTUHSC Garrison Institute on Aging, 2014 – December 2016
  4. Ramesh Kandimalla, Ph.D., TTUHSC Garrison Institute on Aging, October 2014 – August 2016

 

Mentoring Faculty

  1. Maria Manczak, TTUHSC Garrison Institute on Aging and Neurology 2017 January – Present.
  2. Ramesh Kandimalla, TTUHSC Garrison Institute on Aging and Pharmacology/Neuroscience, September 2016 – 2018.
  3. Eunhee Chung, Ph.D., Assistant Professor, Department of Kinesiology and Sport Management, TTU, June 2015-2016, Eunhee moved HSC, San Antonio 2016 August
  4. Vijay Hegde, Ph.D., Assistant Professor, Nutritional Sciences Department, TTU, June 2015 to Present – Received TTU/TTUHSC Presidential Collaborative Research Grant
  5. Peter Keyel, Ph.D. Assistant Professor, Department of Biological Sciences, TTU Jan 2016 to Present – Assisted with an R21 Grant (pending)
  6. Yan-Soo Yoon, Ph.D., Assistant Professor, Department of Speech, Language and Hearing Sciences Department, School of Health Professionals, October 2014 to Present – Received CH Foundation Grant (Co-Investigator)
  7. Andrey Karamyshev, Ph.D., Assistant Professor, Department of Cell Biology and Biochemistry, TTUHSC
  8. Josh Lawrence, Associate Professor, Pharmacology/Neuroscience, TTUHSC September 2015 – Present

 

Other Supervising Staff

  1. Kandi Quesada, BBA, TTUHSC Garrison Institute on Aging, May 2015 – Present.
  2. Kathleen Stonum, Unit Coordinator, Garrison Institute on Aging Lubbock, April 2015 – Present
  3. Annette Boles, TUHSC Garrison Institute on Aging, October 2014 – Present.
  4. Joan Blackman, MBA., TUHSC Garrison Institute on Aging, October 2014 – Present
  5. Veronica Molinar-Lopez., B.S., TUHSC Garrison Institute on Aging, October 2014 – Present
  6. Clay Ament, B.S., TUHSC Garrison Institute on Aging, October 2014 – Present
  7. Susan Thomson, TUHSC Garrison Institute on Aging, October 2017 – Present

 

Mentoring Past

High School Students

  1. Kajal Parikh, TTUHSC Garrison Institute on Aging June 2015 to August 2015

 

Mentoring Faculty

  1. Akhilesh Pandey, Research Faculty, TTUHSC Garrison Institute on Aging/Department of Neurology, October 2014 – August 2015.

 

Postdoctoral Research Associate

  1. Jinhua Luo, Ph.D. 2008-2015

 

Oregon Health & Science University

  1. Daniel Meza, B.S. Research Technician 2012-2014
  2. Jennifer Day, B.S. Research Assistant (2013)
  3. Ulziibat Shirendeb, Ph. D. Postdoctoral Fellow (2009-2011)
  4. Peizhong Mao, Ph.D. Staff Scientist 1 (2008-2012), faculty at OHSU
  5. Marcus Calkins, Ph.D. Postdoctoral Fellow (2009-2011), faculty at Taiwan
  6. Arubala P. Reddy, Ph.D. Research Associate (2009-2010), faculty at TTUHSC
  7. Divya Shree, Ph.D. Postdoctoral Fellow (2008-2009)
  8. Chelsy Kline, B.S., Visiting Scientist from Pacific University (2007-2008), postdoc at OHSU
  9. Wei Zhao, Ph.D. Postdoctoral Fellow (2007-2008)
  10. Maria Manczak, Ph.D. Post-doctoral Fellow (2003-2005)
  11. Thimmappa S Anekonda, Ph.D. Post-doctoral Fellow (2005-2006), small business owner
  12. Gutala Ramana, Ph.D. Postdoctoral Fellow (2001-2002)
  13. Rui Yang, MD, Postdoctoral Fellow (2001-2002), doctor in Eugene, Oregon
  14. Dara Partovi, B.S., Research Assistant II (2004-2006)
  15. Geethalakshmi, MBBS, Research Assistant II (2000-2003), General Physician in Iowa

 

Summer/Winter Interns present and past

  1. Nivedita Mandal (2013 Saturday Academy Student), Currently doing BS/MD
  2. Liz Berg (2013 Undergraduate Intern)
  3. Maanas Tripathi 2012 (Undergraduate Student), Currently doing MD
  4. Vishwanath Anekonda 2011 (Undergraduate Student), Currently doing MD
  5. Daniel Wong 2012 (Saturday Academy High School Student)
  6. Raghav Tripathi 2011 (Saturday Academy High School Student) – Awarded first place in the district science fair competition and won 5 awards, including Best of Fair in Cellular and Molecular Biology at the Intel International Science & Engineering Fair competition 2012, Pittsburgh, currently doing BS/MD

 

  1. Tejaswini P. Reddy 2010 High School Student – awarded first place in the district science fair competition, best of the faif at NORTHWEST SCIENCE EXPO, Portland and won several awards at the Intel International Science & Engineering Fair competition 2011, Los Angeles – MD/PhD at Texas A&M 2016-2023.

 

  1. Qunag Truong 2010 (Saturday Academy Student)
  2. Karuna Tirumala 2010 (Saturday Academy Student)
  3. Nevedha Rajan 2009 (Saturday Academy Student), currently doing MD
  4. Margaret G. McCue 2009 Jan-2009 March, currently doing PhD at Harvard/MIT
  5. Patience Gallagher 2008-Summer intern, currently doing MD
  6. Samira Nedungadi 2008-Summer intern
  7. Evelin Sun 2004-Summer intern
  8. Youngsin Jung 2003-Summer intern- completed MD/PhD at UT Houston
  9. Erin Flarety 2003-Summer intern postdoc
  10. Rahul Kasukurthy 2002-Summer intern, completed MD-full doctor
  11. Joline Jauqes 2002-Summer intern, postdoc now
  12. Jonathan Bekke 2001-Summer intern, postdoc now

 

Mentoring Past at Human Genome Project, NIH, Bethesda, MD

  1. Gabriel Bien Willner- Pre IRTA Fellow (July 1999-June 2000) MD
  2. Jack P. Ayoub – Pre IRTA fellow (Sept1998-August 1999) MD
  3. Maya Williams- Pre IRTA Fellow (Oct 1996-August 1998), PhD
  4. Elaine Stockburger (1996-Summer intern), Established Vet

 

Organizing Regional Healthy Aging and Dementia Research October 24-25, 2018

My colleagues and I from Garrison Institute on Aging of The Texas Tech University Health Sciences Center (TTUHSC) Garrison Institute on Aging will be hosting the Regional Healthy Aging And Dementia Research Symposium Oct. 24 – 25 at the Texas Tech University International Cultural Center, Hall of Nations 601 Indiana Ave.
The Research Symposium will feature experts primarily focused on dementia and neurodegenerative diseases research, public health trends focused on neurodegenerative diseases of aging and community-based research focused on health, nutrition and cognition.
P. Hemachandra Reddy, Ph.D., executive director and chief scientific officer of the Garrison Institute on Aging, said the event will give participants an opportunity to interact with representatives of advocacy groups and experts on healthy aging and dementia research. With more than 50 million people living with Alzheimer’s disease and other dementias worldwide, the Garrison Institute on Aging is committed to provide forums such as this symposium to connect experts across all universities and institutes in order to share knowledge about aging and dementias. Details of symposium can be found in the website below:

 

https://dailydose.ttuhsc.edu/2018/september/healthyagingsymposium.aspx

 

International Recognition

Received Bharat Gaurav Award from India-International Friendship Society, Government of India for excellent contributions to Science and Technology.

 

Research on Huntington’s Disease is Highlighted/Telecasted in KLBK and KAMC TV channels –   http://www.everythinglubbock.com/news/klbk-news/a-groundbreaking-discovery-for-science-and-a-new-sense-of-hope-for-patients

 

 

Research on Huntington’s Disease is also covered in Lubbock Avalanche on January 4-5, 2016 – http://lubbockonline.com/local-news/2016-01-04/local-researchers-working-find-treatment-huntingtons-disease#.Vs5DgpMrJBw

 

Websites that covered Huntington’s Disease research published in Human Molecular Genetics – December 2015.

 

http://dailydose.ttuhsc.edu/2016/january/hope-for-huntingtons-disease-patients.aspx

 

http://www.prweb.com/releases/2016/01/prweb13178429.htm

 

http://huntingtonsdiseasenews.com/2016/01/25/sent-by-email/

 

http://huntingtonsdiseasenews.com/2016/01/29/hope-for-huntingtons-disease-patients-texas-tech-university-health-sciences-center-researchers-identify-promising-molecule-for-treatment-of-huntingtons-disease/

 

 

Press Releases of Dr. Reddy’s Research

 

  1. Hemachandra Reddy, Ph.D., Executive Director and Chief Scientific Officer, Mildred and Shirley L. Garrison Chair in Aging, Professor of Cell Biology and Biochemistry, Neuroscience & Pharmacology and Neurology Departments, TTUHSC has participated in conferences that were held in Chandigarh, India, October 26 to November 2, 2015.

 

  1. International Brain Research Organization, Invited Presentation on October 29, 2015

 

Title: Is Impaired Mitochondria Dynamics A Key Factor For Aging and Alzheimer’s Disease? 

 

Abstract: Synaptic pathology and mitochondrial oxidative damage are early events in Alzheimer’s disease (AD) progression. Loss of synapses and synaptic damage are the best correlates of cognitive deficits found in AD patients. Recent research on amyloid beta (Aβ) and mitochondria in AD revealed that Aβ accumulates in synapses and synaptic mitochondria, leading to abnormal mitochondrial dynamics and synaptic degeneration in AD neurons. Increasing evidence suggests that Ab and phosphorylated tau interact with the mitochondrial fission protein, Drp1, causing excessive fragmentation of mitochondria and leading to abnormal mitochondrial dynamics and synaptic degeneration in AD neurons. In addition, recent studies using live-cell imaging and primary neurons from amyloid beta precursor protein transgenic mice revealed reduced mitochondrial mass, defective axonal transport of mitochondria and synaptic degeneration, indicating that Aβ is responsible for mitochondrial and synaptic deficiencies. I will discuss the recent advancements in AD research focusing on impaired mitochondrial dynamics and synaptic damage, and I will also discuss the current status of mitochondria-targeted therapeutics.

 

  1. Indian Neuroscience Academy – 33rd Annual Conference.

Plenary Lecture on October 31, 2015

 

Title: Mitochondrial Division Inhibitor 1 Protects Against Mutant Huntingtin-induced Abnormal Mitochondrial Dynamics and Neuronal Damage in Huntington’s Disease

 

Abstract: Huntington’s disease (HD) is an autosomal, dominantly inherited neurodegenerative disease, characterized by chorea, seizures, involuntary movements, dystonia, cognitive decline, intellectual impairment, and emotional disturbances. Currently, there are no drugs or agents available to treat or to prevent HD. The objective of this study was to determine the protective effects of the mitochondrial division inhibitor 1 (Mdivi1) in striatal neurons that stably express mutant Htt (STHDhQ111/Q111) and wild-type (WT) Htt (STHDhQ7/Q7). Using gene expression analysis, biochemical methods, transmission electron microscopy (TEM) and confocal microscopy methods, we studied 1) mitochondrial and synaptic activities by measuring mRNA and the protein levels of mitochondrial and synaptic genes, 2) mitochondrial function and 3) ultra-structural changes in mutant Htt neurons relative to WT Htt neurons.  We also studied these parameters in Mdivil-treated and untreated WT and mutant Htt neurons. Increased expressions of mitochondrial fission genes, decreased expression of fusion genes and synaptic genes were found in the mutant Htt neurons relative to the WT Htt neurons. Electron microscopy of the mutant Htt neurons revealed a significantly increased number of mitochondria, indicating that mutant Htt fragments mitochondria. Biochemical analysis revealed defective mitochondrial functioning. In the Mdivil-treated mutant Htt neurons, fission genes were down-regulated, and fusion genes were up-regulated, suggesting that Mdivil decreases fission activity. Synaptic genes were up-regulated, and mitochondrial function was normal in the Mdivi1-treated mutant Htt neurons. Immunoblotting findings of mitochondrial and synaptic proteins agreed with mRNA findings.  The transmission electron microscopy studies revealed that increased numbers of structurally intact mitochondria were present in Mdivi1-treated mutant Htt neurons. Taken together, these findings suggest that Mdivi1 is protective against mutant Htt-induced mitochondrial and synaptic damage in HD neurons and that Mdivi1 may be a promising molecule for the treatment of HD patients.

 

Websites that covered news of Dr. Reddy’s presentations at International Brain Research Organization Conference held in Chandigarh, India October 29-31, 2015.

 

http://indianexpress.com/article/cities/chandigarh/scientists-to-share-experiences-and-training-on-the-role-of-mitochondria-in-nervous-system/

 

http://www.tribuneindia.com/news/chandigarh/education/ibro-school-faculty-to-dwell-on-mitochondria-its-aspects/149846.html

 

http://www.cityairnews.com/content/five-day-international-school-mitochondria-and-brain-pu

 

http://www.indianewscalling.com/education/news/30534-mitochondrial-impairment-is-a-key-factor-of-aging-and-disease-of-forgetfulness-and-women-are-at-high.aspx

 

http://punjabnewsexpress.com/health/news/-mitochonidrial-impairment-is-a-key-factor-of-agingsays-us-professor-44675.aspx

 

http://www.babushahi.com/news-detail.php?id=52615#jump0

 

http://www.embed3k.net/21857/scientists-to-share-experiences-and-training-on-the-role-of-mitochondria-in-nervous-system.html

 

http://www.dailypost.in/regions/chandigarh/51214-migraine-needs-more-attention-dr-shukla

 

 

Press Releases from Oregon Health and Science University – NIH Study Section Chartered Member Status 2013-2019

 

  1. Hemachandra Reddy, Ph.D., an associate scientist in the Division of Neuroscience, has been selected to serve as a member of the Neural Oxidative Metabolism and Death Study Section for the NIH Center for Scientific Review through June 30, 2019. Members are selected based on the quality of their research accomplishments, publications in scientific journals, and other significant scientific activities, achievements and honors. As a member of a study section, Dr. Reddy will review NIH grant applications and survey the status of research in his area of expertise. Congratulations to Dr. Reddy on this new appointment.

 

http://www.ohsu.edu/blogs/researchnews/2013/07/09/p-hemchandra-reddy-appointed-to-nih-neural-oxidative-metabolism-and-death-study-section/

 

2013

  1. Press Release from Oregon Health and Science University about multiple sclerosis mouse model and mitochondria-targeted quinone – MitoQ treatment publication

 

Mao P, Manczak M, Shirendeb UP, Reddy PH. MitoQ, a mitochondria-targeted antioxidant, delays disease progression and alleviates pathogenesis in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis. Biochim Biophys Acta. 2013 Dec;1832(12):2322-31.

 

Abstract. Oxidative stress and mitochondrial dysfunction are involved in the progression and pathogenesis of multiple sclerosis (MS). MitoQ is a mitochondria-targeted antioxidant that has a neuroprotective role in several mitochondrial and neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease. Here we sought to determine the possible effects of a systematic administration of MitoQ as a therapy, using an experimental autoimmune encephalomyelitis (EAE) mouse model. We studied the beneficial effects of MitoQ in EAE mice that mimic MS like symptoms by treating EAE mice with MitoQ and pretreated C57BL6 mice with MitoQ plus EAE induction. We found that pretreatment  and treatment of EAE mice with MitoQ reduced neurological disabilities associated with EAE. We also found that both pretreatment and treatment of the EAE mice with MitoQ significantly suppressed inflammatory markers of EAE, including the inhibition of inflammatory cytokines and chemokines. MitoQ treatments reduced neuronal cell loss in the spinal cord, a factor underlying motor disability in EAE mice. The neuroprotective role of MitoQ was confirmed by a neuron-glia co-culture system designed to mimic the mechanism of MS and EAE in vitro. We found that axonal inflammation and oxidative stress are associated with impaired behavioral functions in the EAE mouse model and that treatment with MitoQ can exert protective effects on neurons and reduce axonal inflammation and oxidative  stress. These protective effects are likely via multiple mechanisms, including the attenuation of the robust immune response. These results suggest that MitoQ may be a new candidate for the treatment of MS.

 

Press Click on the Websites for Press Release

http://www.ohsu.edu/xd/about/news_events/news/2013/12-26-antioxidant-drug-knocks.cfm

 

http://bionews-tx.com/news/2014/01/15/antioxidant-drug-shown-to-significantly-reverse-multiple-sclerosis-like-disease-in-mice/

 

http://www.emaxhealth.com/1275/old-antioxidant-drug-could-be-new-ms-treatment

 

http://news.softpedia.com/news/Old-Drug-May-Be-Used-to-Fight-Multiple-Sclerosis-412473.shtml

http://www.natureworldnews.com/articles/5449/20131227/new-treatment-ms-found-old-medicine.htm

 

http://www.newsmax.com/Health/Health-News/ms-antioxidant-multiple-sclerosis/2014/01/02/id/544884/

 

 

Manczak M, Reddy PH. Abnormal interaction of oligomeric amyloid-β with phosphorylated tau: implications to synaptic dysfunction and neuronal damage. J Alzheimers Dis. 2013;36(2):285-95.

 

  1. Press Release from Oregon Health and Science University about Amyloid beta interaction phosphorylated tau in Alzheimer’s disease pathogenesis

 

Abstract

Alzheimer’s disease (AD) is a progressive neurodegenerative mental illness characterized by memory loss, multiple cognitive impairments, and changes in personality and behavior. The purpose of our study was to determine the interaction between monomeric and oligomeric amyloid-β (Aβ) and phosphorylated tau in AD neurons. Using postmortem brains from AD patients at different stages of disease progression and control subjects, and also from AβPP, AβPPxPS1, and 3xTg-AD mice, we studied the physical interaction between Aβ and phosphorylated tau. Using immunohistological and double-immunofluorescence analyses, we also studied the localization of monomeric and oligomeric Aβ with phosphorylated tau. We found monomeric and oligomeric Aβ interacted with phosphorylated tau in neurons affected by AD. Further, these interactions progressively increased with the disease process. These findings led us to conclude that Aβ interacts with phosphorylated tau and may damage neuronal structure and function, particularly synapses, leading to cognitive decline in AD patients. Our findings suggest that binding sites between Aβ and phosphorylated tau need to be identified and molecules developed to inhibit this interaction.

 

Press Click on the Websites for Press Release

http://www.ohsu.edu/xd/about/news_events/news/2013/06-18-new-alzheimers-research.cfm

 

http://www.oregonlive.com/health/index.ssf/2013/06/new_research_sheds_light_on_po.html?&co=f000000009816s-1158206718

 

http://www.iospress.nl/ios_news/new-alzheimers-research-suggests-possible-cause-the-interaction-of-proteins-in-the-brain/

 

http://www.j-alz.com/content/new-alzheimers-research-suggests-possible-cause-interaction-proteins-brain

 

 

Please Click on OHSU Brain Institute Website Press Release

http://www.ohsu.edu/blogs/brain/2013/06/26/the-continuing-search-for-the-answer-to-alzheimers-disease/

 

 

2006

Alzheimer Award 2006 from Journal of Alzheimer’s Disease

2006 Alzheimer Award to P. Hemachandra Reddy, PhD

 

Dr. George Perry, Editor-in-Chief of Journal of Alzheimer’s Disease, CASE WESTERN RESERVE UNIVERSITY

 

The 2006 Alzheimer Award is being presented to P. Hemachandra Reddy, Ph.D., in recognition of his outstanding work published in the Journal of Alzheimer’s Disease (IOS Press, Volume 7, 2005, 103-117), “Differential loss of synaptic proteins in Alzheimer’s disease: Implications for synaptic dysfunction” by P. Hemachandra Reddy, Geethalakshmi Mani, Byung S. Park, Joline Jacques, Geoffrey Murdoch, William Whetsell Jr., Jeffrey Kaye, and Maria Manczak. The work was performed at the Neurological Sciences Institute, West Campus, Oregon Health & Science University, Beaverton, OR, USA.

 

Synaptic pathology is a prominent feature of Alzheimer’s disease and strongly correlates with cognitive impairments. Synaptic damage occurs early in AD development, suggesting that synaptic alterations are a primary event in the progression of AD. However, the underlying mechanisms of synaptic pathology in AD are not completely understood. The main objective of the research awarded the prize was to determine whether presynaptic or postsynaptic compartments of neurons in AD patients are preferentially affected by disease. Using immunoblotting, immunohistochemistry, and densitometry techniques, Reddy and his colleagues investigated 7 synaptic proteins in a large number of postmortem brains from AD patients and age-matched control subjects. They found a selective loss of both presynaptic and post synaptic proteins in the postmortem brains from the AD patients relative to those from the age-matched control subjects. Of the 7 proteins studied, the presynaptic proteins synaptophysin and rab 3A, and the postsynaptic protein synaptopodin were the most down-regulated. In addition, this paper is the first to report on the loss of synaptopodin in the postmortem brains from AD patients – a finding that beckons further investigation of postsynaptic proteins in AD patients.

 

  1. Hemachandra Reddy was a commonwealth scholar (1990-1993) before receiving his Ph.D. (1994) from University College, London University. He did his postdoctoral training (1995-2000) with Dr. Danilo A. Tagle at the National Human Genome Research Institute, National Institutes of Health, Bethesda, MD. In his post-doctoral research, Dr. Reddy isolated and characterized cDNAs containing polymorphic polyglutamine (CAG)n repeats in the adult human brain cDNA library. In 1998, Dr. Reddy was the first researcher to develop a transgenic mouse model for Huntington’s disease (HD) using full-length HD cDNA. This mouse model showed progressive phenotypic behavior and selective neurodegeneration in the striatum and cortex. After his postdoctoral training, Dr. Reddy joined the Neurological Sciences Institute Faculty at Oregon Health & Science University (OHSU) in July 2000 and established the OHSU Neurogenetics Laboratory. The research focus in the Reddy laboratory is on understanding molecular and cellular bases of neurodegenerative diseases. Currently, the Reddy laboratory is focusing on unraveling the connection between amyloid-ß (Aß) and synaptic damage, and Aß and mitochondrial oxidative damage in AD.

 

Each year the Associate Editors of the Journal of Alzheimer’s Disease select the award recipient from among articles published in the previous year’s volume. The awardee will receive the Alzheimer Medal, a handsome bronze medal with the likeness of Alois Alzheimer as well as a cash award. Former winners include Lester I. Binder, PhD, Massimo Tabaton, MD, Thomas Wisniewski, MD, Luciano D’Adamio, MD, PhD, Suzanne de la Monte, MD, MPH, Hideo Hara, M.D. and Takeshi Tabira, M.D., Ph.D.

This annual award is generously sponsored by Elan Pharmaceuticals.

 

http://www.eurekalert.org/pub_releases/2006-05/cwru-2aa050506.php

 

http://www.j-alz.com/press/2006/20060505.html

 

2006

Manczak M, Anekonda TS, Henson E, Park BS, Quinn J, Reddy PH. Mitochondria are a direct site of A beta accumulation in Alzheimer’s disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet. 2006 May 1;15(9):1437-1449.

 

Abstract

Alzheimer’s disease (AD) is a complex, neurodegenerative disease characterized by the impairment of cognitive function in elderly individuals. In a recent global gene expression study of APP transgenic mice, we found elevated expression of mitochondrial genes, which we hypothesize represents a compensatory response because of mitochondrial oxidative damage caused by the over-expression of mutant APP and/or amyloid beta (Aβ). We investigated this hypothesis in a series of experiments examining what forms of APP and Aβ localize to the mitochondria, and whether the presence of these species is associated with mitochondrial dysfunction and oxidative damage. Using immunoblotting, digitonin fractionation, immunofluorescence, and electron microscopy techniques, we found a relationship between mutant APP derivatives and mitochondria in brain slices from Tg2576 mice and in mouse neuroblastoma cells expressing mutant human APP. Further, to determine the functional relationship between mutant APP/Aβ and oxidative damage, we quantified Aβ levels, hydrogen peroxide production, cytochrome oxidase activity and carbonyl proteins in Tg2576 mice and age-matched wild-type (WT) littermates. Hydrogen peroxide levels were found to be significantly increased in Tg2576 mice when compared with age-matched WT littermates and directly correlated with levels of soluble Aβ in Tg2576 mice, suggesting that soluble Aβ may be responsible for the production of hydrogen peroxide in AD progression in Tg2576 mice. Cytochrome c oxidase activity was found to be decreased in Tg2576 mice when compared with age-matched WT littermates, suggesting that mutant APP and soluble Aβ impair mitochondrial metabolism in AD development and progression. An increase in hydrogen peroxide and a decrease in cytochrome oxidase activity were found in young Tg2576 mice, prior to the appearance of Aβ plaques. These findings suggest that early mitochondrially targeted therapeutic interventions may be effective in delaying AD progression in elderly individuals and in treating AD patients.

 

http://www.eurekalert.org/pub_releases/2006-05/ohs-orr043006.php

 

http://www.ohsu.edu/xd/about/news_events/news/2006/05-01-ohsus-neurological-scie.cfm

 

http://www.sciencedaily.com/releases/2006/05/060501113535.htm

 

2005

Reddy PH, Mani G, Park BS, Jacques J, Murdoch G, Whetsell W Jr, Kaye J, Manczak M. Differential loss of synaptic proteins in Alzheimer’s disease: implications for synaptic dysfunction. J Alzheimers Dis. 2005 Apr;7(2):103-17;discussion 173-80.

 

Abstract

The objective of our research was to determine synaptic protein levels in brain specimens from AD subjects and age-matched control subjects. Further, to determine whether presynaptic or postsynaptic compartments of neurons are preferentially affected in AD patients, we studied 3 presynaptic vesicle proteins (synaptotagmin, synaptophysin, and Rab 3A), 2 synaptic membrane proteins (Gap 43 and synaptobrevin), and 2 postsynaptic proteins (neurogranin and synaptopodin) in specimens from AD and age-matched control brains. Two brain regions–the frontal and parietal cortices–were assessed for protein levels by immunoblotting analysis. We found a loss of both presynaptic vesicle proteins and postsynaptic proteins in all brain specimens from AD patients compared to those from age-matched control subjects. Further, we found that the loss of synaptic proteins was more severe in the frontal cortex brain specimens than in the parietal cortex brain specimens from the AD subjects compared to those from the control subjects, suggesting that the frontal brain may be critical for synaptic function in AD. Using immunohistochemistry techniques, we also determined the distribution pattern of all synaptic proteins in both the frontal and parietal cortices brain specimens from control subjects. Of the 7 synaptic proteins studied, the presynaptic proteins synaptophysin and rab 3A and the postsynaptic protein synaptopodin were the most down-regulated. Our study suggests that postsynaptic proteins and presynaptic proteins are important for synaptic function and may be related to cognitive impairments in AD.

 

Press Click on the Website for Press Release

http://www.ohsu.edu/xd/about/news_events/news/2005/04-07-ohsu-researchers-demonst.cfm

 

 

2004

Reddy PH, McWeeney S, Park BS, Manczak M, Gutala RV, Partovi D, Jung Y, Yau V, Searles R, Mori M, Quinn J. Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and  apoptotic genes is an early cellular change in Alzheimer’s disease. Hum Mol Genet. 2004 Jun 15;13(12):1225-1240.

 

Abstract

Alzheimer’s disease (AD) is a progressive neurodegenerative disease characterized by the impairment of cognitive functions and by beta amyloid (Abeta) plaques in the cerebral cortex and the hippocampus. Our objective was to determine genes that are critical for cellular changes in AD progression, with particular emphasis on changes early in disease progression. We investigated an established amyloid precursor protein (APP) transgenic mouse model (the Tg2576 mouse model) for gene expression profiles at three stages of disease progression: long before (2 months of age), immediately before (5 months) and after (18 months) the appearance of Abeta plaques. Using cDNA microarray techniques, we measured mRNA levels in 11 283 cDNA clones from the cerebral cortex of Tg2576 mice and age-matched wild-type (WT) mice at each of the three time points. This gene expression analysis revealed that the genes related to mitochondrial energy metabolism and apoptosis were up-regulated in 2-month-old Tg2576 mice and that the same genes were up-regulated at 5 and 18 months of age. These microarray results were confirmed using northern blot analysis. Results from in situ hybridization of mitochondrial genes-ATPase-6, heat-shock protein 86 and programmed cell death gene 8-suggest that the granule cells of the hippocampal dentate gyrus and the pyramidal neurons in the hippocampus and the cerebral cortex are up-regulated in Tg2576 mice compared with WT mice. Results from double-labeling in situ hybridization suggest that in Tg2576 mice only selective, over-expressed neurons with the mitochondrial gene ATPase-6 undergo oxidative damage. These results, therefore, suggest that mitochondrial energy metabolism is impaired by the expression of mutant APP and/or Abeta, and that the up-regulation of mitochondrial genes is a compensatory response. These findings have important implications for understanding the mechanism of Abeta toxicity in AD and for developing therapeutic strategies for AD.

 

Press Click on the Websites for Press Release

http://www.eurekalert.org/pub_releases/2004-04/ohs-oru042704.php

 

http://www.indolink.com/printArticleS.php?id=042904095615

 

http://www.prohealth.com/library/showarticle.cfm?libid=5849

 

Leave a Reply

Your email address will not be published. Required fields are marked *